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The UCT Drug Discovery and Design Centre, H3D, provided anti-tubercular and antimalarial 
drug leads that display potent in vitro activity, but with unfavourable physicochemical 
properties. The primary objective of this study was to prepare supramolecular derivatives of 
the drug leads in an attempt to improve their physicochemical properties. Any new solid 
forms were to be characterized by a variety of analytical techniques, including X-ray 
analysis, spectroscopic and thermal techniques. Where possible, such derivatives would be 
tested for any enhancement in the aqueous solubility or biological activity of the drug lead. 
The second objective of this study was to employ supramolecular intervention in the early 
stages of the drug discovery and development process to help streamline the process by 
distinguishing between compounds that might be amenable to beneficiation via 
supramolecular modification and those that might not. 
 
The crystal structure of a novel anti-tubercular drug lead, DL2, was solved and the 
compound was fully characterized using thermal and X-ray techniques. This compound 
displayed very poor solubility in both aqueous and organic media. 
 
Phase solubility studies were performed with anti-tubercular drug lead DL3 and selected 
cyclodextrins (CDs). The apparent solubility of DL3 increased by a factor of more than 300 at 
the highest concentration of hydroxypropyl- β-CD (HPβCD) and β-CD investigated.  
 
Three salts of antimalarial drug lead DL4 and carboxylic acids were prepared. The salts 
were characterized by X-ray and thermal techniques. A salt of citric acid and DL4 could be 
prepared by the liquid-assisted grinding method. The equilibrium solubility of this salt was 48 
times greater than that of DL4. 
 
An inclusion complex between DL4 and a partially methylated cyclodextrin (DIMEB) was 
prepared and fully characterized. Phase solubility analysis showed that the aqueous 
solubility of DL4 increased by a factor of 100 at the highest concentration of DIMEB 
investigated. Mice infected with P. berghei were dosed with capsules containing 5 mg kg-1 of 
inclusion complex for in vivo pharmacokinetic testing. The results are consistent with a slow 
release of DL4 from the inclusion complex, resulting in a longer sustained concentration of 
DL4 over time as seen from the increase in apparent half-life. In vivo efficacy studies 
showed that the antimalarial activity of the inclusion complex was more than double that of 
DL4 at a dose of 3 mg kg-1. 
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CHAPTER 1: INTRODUCTION 
 
Supramolecular beneficiation of pharmaceuticals  
 
The ability to manipulate solids through the control of crystal packing provides an 
enormous benefit to the pharmaceutical industry. Crystalline forms of drugs are 
favoured by the pharmaceutical industry because they are reproducible, they tend to 
be more stable than other forms and purification of crystalline forms can be achieved 
with much less effort than other types of solid forms. Over the past 50 years the 
understanding of intermolecular interactions as they relate to crystal packing has 
evolved1 and crystal engineering has emerged as one of the main ways in which this 
knowledge of intermolecular interactions and crystals can be exploited to design new 
solids.2 An in-depth understanding of the supramolecular chemistry of the functional 
groups present in a molecule is critical in crystal engineering.3 An understanding of 
complementary hydrogen bonding is also vital for selecting molecules which may 
form supramolecular synthons with drug molecules (Figure 1).4 
 
 
Figure 1: Common supramolecular synthons. 1 and 3 are acid-acid homosynthons with graph-set 
notation 𝑹𝟐𝟐(𝟖) and 𝑪(𝟒) respectively. 2 and 4 are amide-amide homosynthons with graph-set notation 
𝑹𝟐
𝟐(𝟖) and 𝑪(𝟒) respectively. 
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It has been shown that supramolecular derivatisation of drugs can result in new solid 
forms with improved solid-state properties such as enhanced aqueous solubility, 
more facile compressibility and reduced hygroscopicity.3,5  
 
Pharmaceutical salts and co-crystals  
 
 Co-crystals are multi-component crystalline systems consisting of more than one 
chemical entity in the crystal. For a multi-component system to be considered a            
co-crystal, all of the components must be in neutral form and exist as solids at room 
temperature, according to one widely-used definition.3 These criteria distinguish              
co-crystals from salts (where the components are in ionic form) and solvates (where 
at least one component is a liquid at room temperature). The different components in 
a co-crystal are linked by non-covalent interactions such as directed hydrogen 
bonding and the molecules are present in distinct stoichiometric ratios.3 
 
Co-crystals can be prepared using the crystal engineering approach which typically 
involves the systematic selection of appropriate co-crystal formers followed by 
experimental work to synthesise the desired product. In the study described in this 
dissertation, all of the co-formers that were used appear on the Food and Drug 
Administration (FDA) “generally regarded as safe” (GRAS) database.6  
 
An example of a co-crystal study from the literature can be found in the report by 
Caira et al, where five novel co-crystals of the antiretroviral drug Nevirapine were 
isolated. The study showed that the co-crystal of Nevirapine and maleic acid (Figure 
2) had an aqueous solubility that was five times that of the untreated drug.7 
 
 
Figure 2: Complementary hydrogen bonding between Nevirapine and the maleic acid co-former.7 
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The formation of a salt is the result of an acid-base type of reaction that occurs when 
there is a proton transfer from an acidic to a basic component.8 The components in a 
salt exist in ionic form and this is the major chemical feature that distinguishes a salt 
from a co-crystal. The pKa values of the components are believed to play a role in 
the formation of salts or co-crystals. The difference in the pKa values                     
(ΔpKa = [pKa(base) – pKa(acid)]) of the components is assumed to be the driving 
force behind proton transfer, with ΔpKa = 3 generally corresponding to salt 
formation.8 Although the ΔpKa values do play a role in the formation of co-crystals vs. 
salts, these values should not be interpreted in isolation, but rather regarded as one 
of the factors to be considered in the crystal engineering process. 
 
Cyclodextrins: general overview 
 
Cyclodextrins (CDs) were first described by Villiers in the late 1800s and the term 
“cyclodextrin” was later coined by the Austrian chemist Franz Schardinger.9-10 The 
native CDs are composed of six, seven or eight α-1,4 linked D-glucopyranose rings 
(α-, β- and γ-CD respectively) as shown in Figure 3. CDs have a narrower primary 
rim and a wider secondary rim, resulting in the molecule adopting a truncated cone 
shape [Figure 3(b)]. The primary rim possesses one primary hydroxyl group (O6–H) 
per glucose unit and the secondary rim has two hydroxyl groups (O2–H and O3–H) 
per glucose unit. α-, β- and γ-CD have comparatively low aqueous solubility at 25 °C 
(14.5, 1.85 and 23.2 g per 100 cm3 respectively) relative to derivatised CDs. This is 
most probably a result of the strong binding of the CD molecules in the crystalline 
state. Furthermore, of the three native CDs, β-CD molecules form the strongest 
intramolecular O–H•••O hydrogen bonds that inhibit their ability to form hydrogen 
bonds with water molecules, thus resulting in this member of the series having the 
lowest solubility. Substituting any of the hydroxyl groups with a methoxy group can 
lead to significant physicochemical changes and the resulting derivatised CDs are 
generally more water soluble than native CDs. Despite this advantage, they are 
generally more toxic, although DIMEB and HPβCD and HPγCD have been used in 
formulations for pharmaceutical products.11-13  




Figure 3: (a) an  D-glucopyranose unit, (b) the truncated cone shape showing the narrow primary rim 
and wider secondary rim, (c) left to right: macrocyclic rings of -, β- and γ-CD. 
 
Molecular geometry  
 
A number of geometrical parameters are used to describe the macrocylic 
conformation of CDs. By comparing the conformation of complexed and 
uncomplexed hosts, one can obtain valuable information about the effect that the 
guest has on the conformation of the host. The geometric parameters, defined by 
Harata and Saenger, are based on the O4 atoms that are used to construct the         
O4-heptagon (in the case of β-CD and its derivatives) from which angles and 
distances can be measured.14-15 The geometrical parameters that can be measured 
using the O4-heptagon (Figure 4) include the distance from the O4 atom to the 
centroid of the heptagon (𝑙), the O4–O4 distance (D), the O4–O4–O4 angle () and 
the O4–O4–O4–O4 torsion angle (d). If the mean plane through the O4 atoms in 
an undistorted CD molecule were to be calculated, it would pass through all of the 
O4 atoms and all torsion angles (d) would be zero. 




Figure 4: Principal geometric parameters of the O4-heptagon used to describe the conformation of each 
host molecule.   
 
One geometrical parameter that is not directly defined by the O4-heptagon is the 
possible O2•••O3 intramolecular hydrogen bond distance (D3). It is possible to 
measure the deviation of each of the O4 atoms from the mean plane through the O4 
atoms and this deviation is represented by the parameter α. The acute angle 
between the O4 mean plane and the plane through O4, C4, C1 and O4 of a glucose 
ring in the CD is described by the parameter 2. The angle 2 is also referred to as 
the ‘tilt angle’ and it measures the relative inclination (or tilt) of each glucose unit 
relative to the O4 mean plane. Figure 5(a) shows the O4 mean plane through a β-CD 
host molecule and the planes defining the 2 angle for one of the glucose units have 
been shown in Figure 5(b). 
 
 




Figure 5: (a) O4 mean plane through a β-CD host molecule, (b) planes used to calculate 2 for one 
glucose unit in β-CD. Atoms that define a plane have been represented as yellow spheres. 
 
Crystal packing arrangements for cyclodextrins  
 
There are two types of packing arrangements that apply to both monomeric and 
dimeric CD complexes. This first is the channel type packing where the cavities of 
the CD molecules are aligned either head-to-head (dimeric) or head-to-tail 
(monomeric), creating infinite columns (Figure 6). Cage type packing occurs when 
the CD cavity is obstructed on both the primary and secondary rims by neighbouring 
CD molecules. Typical examples of monomeric cage type packing modes are the 
herringbone and brickwork arrangements.  
 
The term isostructurality refers to two or more phases that have the same gross 
packing arrangement and hence similar arrangement of the molecules in the crystal, 
leading to similar unit cell dimensions.16 The gross packing arrangement of 
cyclodextrin complexes is determined by the CD molecules, and thus it is possible 
for two or more complexes with different guest molecules to be considered 
isostructural. This was the subject of the review done by Caira in which he described 
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a series of isostructural PXRD patterns that exist for known CD complexes. It is now 
possible to compare the PXRD patterns from the isostructural series with any PXRD 
pattern resulting from a CD inclusion experiment and thereby determine if any 
complexation has occurred.17 
 
 
Figure 6: Examples of packing arrangements for CD complexes.  
 
Inclusion complexes  
 
The cavity of a CD molecule is able to accommodate guest molecules and reversibly 
bind to them, resulting in an inclusion complex. The central cavity of a CD is 
lipophilic and when a cyclodextrin inclusion complex is formed, lipophilic moieties on 
the guest molecule are involved in non-covalent interactions with the cavity.5 Figure 7 
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is a graphical illustration of the reversible nature of CD inclusion, where                         






Figure 7: Reversible binding that can occur between a guest molecule (G) and a CD in solution. 
 
Pharmaceutical applications of CDs 
 
CDs are able to “mask” insoluble moieties on the guest molecule through the 
formation of inclusion complexes. Thus, poorly soluble compounds can be made 
soluble through the binding of an insoluble moiety to the lipophilic cavity of a CD and 
the favourable hydrogen bonding between the hydroxyl groups on the outer surface 
of the cyclodextrin with water molecules.5 Studies have shown that the formation of 
cyclodextrin inclusion complexes can improve the bioavailabilities of FDA Class II 
drugs primarily i.e. drugs that have poor aqueous solubility and high permeability.12 
 
 
CDs are almost non-toxic when they are administered orally, because they are 
generally not absorbed in the gastrointestinal tract.19 Absorption studies have 
determined that 2-4% of CDs are absorbed in the small intestine with the remainder 
being degraded by α-amalyses and absorbed as glucose.20 Their structures, 
molecular weights and low octanol/water partition coefficients are typical for 
compounds that do not easily cross biological membranes.20-21 The fact that CDs are 
virtually non-toxic, do not readily cross biological membranes and are able to 
solubilise poorly soluble compounds makes them ideal for use in drug formulations.  
 
 
Chapter 1: Introduction 
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Early supramolecular intervention in the drug discovery process 
 
High throughput screening and combinatorial chemistry are just two of the 
techniques that have enabled drug discovery scientists to produce a large number of 
new chemical entities (NCEs). However, it is estimated that only 1 in 5000 NCEs 
actually enters the marketplace as a drug.22 This is due to poor clinical efficacy, 
serious negative side effects, adverse drug reactions and unfavourable drug 
metabolism and pharmacokinetics, among other factors. A successful drug 
candidate should have good pharmacological activity, but safety and 
pharmacokinetics are also essential factors that will ultimately determine the success 
of a drug candidate. 
 
Palucki et al have described strategies for implementing early formulation techniques 
during the drug discovery phase and emphasised the benefits of the early 
identification of an optimal phase in drug discovery.23 In particular, their review 
emphasizes the importance of identifying an optimal crystalline phase during the 
drug discovery phase.  
 
As seen in the schematic workflow in Figure 8, supramolecular intervention during 
the drug discovery stage can help to identify compounds that may present 
challenges during the formulation stage. It can also be used to identify compounds 
that have a combination of good pharmacological activity and favourable 
physicochemical properties for further development. Using supramolecular 
intervention in parallel with drug discovery can ultimately reduce the amount of 
resources, time and money spent on compounds that would inevitably be rejected 
during the preclinical stage.   
 




Figure 8: Schematic workflow for identifying a suitable drug lead for further development. Adapted from 
the review by Palucki et al.23 
 
New drug leads to be investigated  
 
Members of the UCT Drug Discovery and Development Centre, H3D, synthesized 
the four novel drug leads (DLs) that were investigated in this study. All of the drug 
leads displayed excellent in vitro activity (with compound also displaying good in vivo 
activity), but very poor aqueous solubility. The latter could potentially imply limited 
bioavailability and if this limitation is not addressed during the early stages of the 
drug discovery process, it could potentially cause major challenges during the 
development stage.  In this study, supramolecular modification of the drug leads  





Figure 9) is an analogue of a “hit” compound that was identified from the screening 
of a BioFocus Softfocus Kinase library. DL1 is part of a novel series of anti-
tubercular compounds. DL1 displayed excellent activity against the H37Rv strain of 
Mycobacterium tuberculosis (Mtb) with MIC99 (the minimum concentration required to 
inhibit 99% of Mtb) values of 1.2 – 2.3 μM and 9.4 μM in the GAST-Fe (glycerol-
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alanine-salts-Tween-iron) and ADC (albumin-dextrose-catalase) medium 
respectively. The cytotoxicity against the VERO cells (African green monkey kidney 
cell line) was impressive with an IC50 (concentration required for 50% inhibition of 
Mtb) value greater than 259 μM. The solubility in phosphate buffer solution (PBS) at 
pH 7.4 was less than 5.0 μM at 25 °C.  
 
Figure 9: Structure of DL1. 
DL2 and DL3 
 
Ethyl 7-amino-2-benzyl-4-methyl-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-
carboxylate (DL2, Figure 10) and 7-amino-2-(3-chlorobenzyl)-4-methyl-6-(3-methyl-
1,2,4-oxadiazol-5-yl)-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione (DL3, Figure 10) are 
two drug leads from a novel series of anti-tubercular compounds. DL2 was identified 
as a “hit” from a high-throughput screening conducted by the Novartis Institute for 
Tropical Diseases (NITD, Singapore) and was further optimized to obtain DL3. Both 
compounds displayed good activity against the H37Rv strain of MTb with a MIC99 
value of less than 0.16 μM in the GAST-Fe medium for DL2 and DL3. The 
cytotoxicity for both compounds was good with IC50 values greater than 295 μM and 
261 μM against VERO cells for DL2 and DL3 respectively. Both compounds 
displayed poor solubility in PBS at pH 7.4 (7.7 μM and less than 5.0 μM at 25 °C for 
DL2 and DL3 respectively).  
 
Figure 10: Structures of DL2 and DL3. 





3-(6-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)-pyridin-2-amine (DL4, Figure 
11) is a member of a novel series of antimalarial compounds.25 DL4 showed potent 
in vitro activity against both the K1 (multi-drug resistant) and NF54 (sensitive) strains 
of the human malaria parasite Plasmodium falciparum with an IC50 value of            
0.051 μM. It also displayed excellent in vivo antimalarial activity, with 99% reduction 
in parasitemia following the oral administration of a 30 mg kg-1 dose to P. berghei 
infected mice. However, DL4 displayed very poor aqueous solubility (0.121 μg cm-3 
at pH 6.5 at 25 °C). 
 
 
Figure 11: Structure of DL4. 
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Motivations and Objectives  
 
The first motivation for this study was to use supramolecular intervention to obtain 
new solid forms of the selected drug leads with improved physicochemical 
properties, in particular aqueous solubility. The second was to demonstrate the 
effectiveness of employing supramolecular intervention during the early stages of the 
drug discovery process to prevent compound attrition during the later drug 
development stage.  
 
The specific objectives were to: 
 
1. perform co-crystal screening with each drug lead. 
2. attempt CD inclusion with each drug lead. 
3. where a new form was identified, obtain single crystals for X-ray structure 
determination. 
4. characterize any co-crystals, salts or CD inclusion complexes using thermal, 
spectroscopic and X-ray techniques.  
5. where possible, investigate whether the new solid forms display improved 
physicochemical properties or biological activity compared to the untreated 
drug lead.  
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The three drug leads discussed in this dissertation, namely 3-(6-methoxypyridin-3-
yl)-5-(4-methylsulfonylphenyl)-pyridin-2-amine (C18H17N3O3S),1 ethyl 7-amino-2-
benzyl-4-methyl-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate 
(C18H17N3O4) and 7-amino-2-(3-chlorobenzyl)-4-methyl-6-(3-methyl-1,2,4-oxadiazol-
5-yl)-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione (C18H14N5O3Cl), were synthesized and 
provided by the UCT Drug Discovery and Development Centre, H3D (University of 
Cape Town, South Africa). The compounds were used as received. Co-crystal 
formers were purchased from Sigma Aldrich (South Africa) and Acros Organics 
(Geel, Belgium). Cylodextrins were purchased from Cyclolab (Budapest, Hungary) 
and Sigma Aldrich (South Africa). All other materials and solvents used were of 




Co-crystal screening with the drug leads was performed in three stages. The first 
stage involved selecting co-crystal formers with functional groups that had the 
potential to form supramolecular synthons with the functional groups present in the 
drug lead. The Cambridge Structural Database (CSD)2 was used to investigate the 
frequency of these particular supramolecular synthons. All of the co-crystal formers 
that were used appear on the US Food and Drug Administration’s “generally 
regarded as safe” (GRAS) database.3  
The next step in the co-crystal screening process involved co-grinding the drug lead 
with the selected co-crystal formers. All of the co-grinding experiments were 
performed using 10 mg of the drug lead and grinding with an equimolar amount of 
the co-crystal former. In the case of dry co-grinding experiments, the drug lead and 
co-crystal former were ground with a mortar and pestle for 10-15 minutes. The 
product of the dry co-grinding experiment was then analysed using powder X-ray 
diffraction (PXRD) and its trace was compared with the PXRD traces of the two 
separate components. Liquid-assisted co-grinding (LAG) was used extensively as a 
means of generating potential co-crystals. During the LAG experiments, the drug 




lead and co-crystal former were ground for 10-15 minutes while small drops of 
solvent were added to create and maintain a relatively dry paste-like texture. The 
products were analysed using PXRD. 
All PXRD traces from the co-grinding experiments were compared with the PXRD 
traces of the separate components to try and identify any new solid phases that may 
have emerged. If the co-grinding experiments were unsuccessful in creating a new 
solid phase, the PXRD trace of the product would simply be the sum of the PXRD 
traces for the separate components, indicating the formation of a physical mixture of 
the components.  If the PXRD trace of the product was found to contain new peaks, 
or if prominent peaks from one of the separate components were absent in the 
PXRD trace for the co-grinding product, then the trace was considered to be unique 
and indicative of the formation of a new solid phase.  
Co-precipitation experiments were performed in the cases where LAG indicated that 
a new phase had emerged from the combination of a drug lead and a particular       
co-crystal former. In general, stoichiometric amounts of the drug lead and co-crystal 
former were dissolved separately in a common solvent while heating to just below 
the boiling point of the solvent. Once dissolved, the two components were combined 
and the resulting solution was then filtered through a 0.45 μm nylon filter into a clean 
vial. Vials were left on the bench to allow the solvent to evaporate slowly at ambient 
temperature. Suitable crystals were analysed using single crystal X-ray diffraction 
and all supramolecular derivatives were fully characterized. 
  
Cyclodextrin inclusion  
 
Kneading and co-precipitation experiments were carried out with the drug leads and 
cyclodextrins in an attempt to prepare inclusion complexes. For kneading 
experiments the drug leads were combined in a 1:1 molar ratio and kneaded with a 
small volume of water for 15-20 minutes. The products were analysed by PXRD and 
the resulting powder patterns were compared with known calculated patterns for 
common isostructural complexes. If the powder pattern for the kneaded product 
matched one of the calculated traces from the isostructural series,4,5 it was 
considered to be a new inclusion complex with the same packing arrangement as 
the complex from the isostructural series.    




For co-precipitation experiments with the native CDs, the CD was dissolved in           
0.5-1 cm3 Milli-Q6 water at elevated temperature (40-50 °C) and the drug lead was 
added to this solution while stirring. In most cases a small volume of organic solvent 
(ethanol or acetone) had to be added to the solution to facilitate the dissolution of the 
drug lead in the CD solution.  
After stirring at 40-50 °C for 5-24 hours the solutions were filtered through a 0.45 μm 
nylon filter into a clean vial and left on the bench to allow the solvent to evaporate 
slowly. Any suitable single crystals were submitted for unit cell determination to 
establish if an inclusion complex had formed.  
For co-precipitation experiments with the derivatised cyclodextrins, the drug lead 
was dissolved in 1 cm3 of ethanol or acetone while heating and the cyclodextrin was 
dissolved separately in 1 cm3 Milli-Q6 water at room temperature. The two 
components were combined while stirring at room temperature and the solution was 
filtered through a 0.45 μm nylon filter into a clean vial and placed in an oven at 60 °C. 
The vial was left uncapped in the oven for 1.5-2 hours to allow some of the organic 
solvent to evaporate. The solutions were left to crystallize at 50-60 °C. Single 




The thermal methods used to characterise the drug leads and their supramolecular 
derivatives were Hot Stage Microscopy (HSM), Differential Scanning Calorimetry 
(DSC) and Thermogravimetric Analysis (TGA). These three techniques were used in 
combination to analyse the thermal behaviour of the materials.  
 
Thermogravimetric analysis and differential scanning calorimetry 
 
During thermogravimetric analysis a sample is exposed to a nitrogen atmosphere 
and a thermobalance measures the change in the mass of the sample as a function 
of temperature. This method allowed the observation of mass losses corresponding 
to particular components in a crystal. TGA was used extensively as a method to 
quantify the solvent present in crystals. Differential scanning calorimetry measures 
the difference in the energy input between a sample pan and a reference pan as a 




function of temperature. During a DSC experiment the sample pan and the reference 
pan are maintained at a constant temperature and the heat required to maintain this 
state is measured. When the heat flow is plotted as a function of the temperature, it 
is possible to observe endothermic and exothermic peaks corresponding to thermal 
events such as melting, solvent loss or phase transitions.  
 
A TA-Q500 Thermogravimetric Analyzer and DSC-Q200 Differential Scanning 
Calorimeter (TA instruments) with Universal Analysis 2000 software (v4.5A, TA 
Instruments-Waters LLC) were used. Both instruments were operated with a dry 
nitrogen purge gas flow rate of 60 cm3 min-1 and samples were heated at a rate of  
10 K min-1. Samples in the range 1-5 mg were removed from their mother liquor, 
dried on filter paper and placed in an open aluminium crucible or a closed vented 
aluminium pan for TGA and DSC respectively. 
 
Hot stage microscopy 
 
Hot stage microscopy (HSM) was used to confirm the results from TGA and DSC. 
Colour changes, bubbling and changes in the opacity of crystals could be correlated 
with thermal events seen in the TGA and DSC traces. Due to the different sample 
sizes and conditions of the experiments, the temperatures recorded for the HSM 
images are somewhat different from the temperatures recorded for corresponding 
thermal events using TGA or DSC. Samples were monitored using a Nikon SMZ-10 
stereoscopic microscope fitted with a Linkam THMS600 hot stage and a Linkam 
TP92 temperature control unit. Samples were placed on a cover slip with silicone oil 
and images were captured with a real-time Sony Digital Hyper HAD colour video 
camera and viewed using the Soft Imaging System program, analySIS.7 
 
Liquid chromatography-mass spectrometry 
 
The purity of each drug lead was determined using an Agilent® LCMS instrument 
equipped with a photodiode array (PDA) detector. The column was a X-bridge C18  
5 µm (4.6 x 150 mm); organic phase: 10 mM ammonium acetate (pH 3.7) in HPLC 
grade methanol; aqueous phase: 10 mM ammonium acetate (pH 3.7) in HPLC grade 
water. The flow rate was 1.20 cm3 min-1. 




NMR spectroscopy  
 
Drug lead purity was confirmed by 1H NMR and 13C NMR spectroscopy. 1H NMR 
spectroscopy was also used to determine the stoichiometry of CD inclusion 
complexes, co-crystals and salts that were prepared. Crystals were dissolved in 
deuterated DMSO (DMSO–d6) and the 1H NMR spectrum was recorded. For CD 
inclusion complexes the proton signals for the CD and drug lead were integrated to 
determine the host-guest stoichiometry. In the case of co-crystals or salts, the proton 
signals for each component were integrated to confirm the stoichiometry.  The 
spectra were recorded on a Bruker 400 MHz spectrometer.  
 
Fourier Transform Infrared (FTIR) spectroscopy 
 
Fourier Transform Infrared (FTIR) spectroscopy was a useful way of establishing 
whether the product of a co-crystallization experiment was a co-crystal or a salt. By 
careful examination of the characteristic absorption bands of the acidic and basic 
functional groups present in the IR spectra, it was possible to establish whether a 
proton transfer had occurred between the two components. The IR spectra for 
putative co-crystals were recorded on a Bruker Tensor27 spectrometer with an ATR 
platinum Diamond 1 reflectance accessory for solid samples.  
 
Powder X-ray diffraction 
 
Powder X-ray diffraction patterns were recorded to establish whether a co-grinding 
or kneading experiment had resulted in a new crystalline phase. In the case of co-
crystallisation experiments, the PXRD pattern of the product was compared with the 
PXRD patterns of the drug lead and the appropriate co-crystal former. The pattern of 
the product was examined for the emergence of new peaks or the disappearance of 
any peaks from the patterns of the individual components. For the kneading 
experiments the PXRD pattern of the product was compared with a library of 
reference patterns for a known series of isostructural inclusion complexes.4,5 If the 
pattern did not match any of the isostructural patterns and also contained 
superimposed peaks of drug lead, it was concluded that no complexation had taken 
place.  




The idealised PXRD patterns for the X-ray crystal structures that were determined 
were generated from the refined crystallographic data to see if the single crystal was 
representative of the bulk material. The program LAZY PULVERIX8 was used to 
generate idealised PXRD patterns for all of the X-ray crystal structures. LAZY 
PULVERIX uses the formula I(hkl) = mLp│F(hkl)│2, where I(hkl) is the intensity of 
the reflection with indices hkl, m is the reflection multiplicity, L the Lorentz factor, p 
the polarisation factor, and F(hkl) the structure factor.  
 
The powder X-ray diffraction measurements were recorded on a BRUKER D8 
Advance X-ray diffractometer using CuKα-radiation (λ = 1.5406 Å). Samples were 
placed on a zero background sample holder and scanned over the 2θ-range 4 - 40° 
with a step size of 0.02° per second. The X-ray generator settings were 30 kV and 
40 mA.  
 
Crystal structure determination 
 
For single crystal X-ray analysis, crystals of adequate size, quality and optical 
uniformity were removed from the mother liquor and dried on filter paper before 
being coated in Paratone N oil9 and mounted on a nylon cryoloop. In the case of 
complexes of derivatised CDs, the crystals were maintained at 60 °C while being 
removed from the mother liquor and were then immediately dried on filter paper 
before being placed in Paratone N oil. The crystals had to be dried to prevent them 
from dissolving in the mother liquor at room temperature.   
 
Single crystal intensity data were collected on one of two single crystal X-ray 
diffractometers. Either a Nonius KappaCCD (Charge Coupled Device) single crystal 
X-ray diffractometer, using graphite-monochromated MoKα radiation (λ = 0.71069 Å) 
generated by a Nonius FR590 generator operated at 50 kV and 20 mA was used, or 
a Bruker KAPPA APEX II DUO single crystal X-ray diffractometer using MoKα 
radiation (λ=0.71069 Å) generated by a Bruker K780 generator operated at 50 kV 
and 30 mA was used.10 All single crystals were maintained at low temperature      
(173(2) K) during the data-collection by cooling with a constant stream of N2 gas at a 
flow rate of 20 cm3 min-1 with a Cryostream cooler (Oxford Cryostreams, UK). Unit 
cell refinement and data reduction were performed using the programs DENZO and 




SCALEPACK11 or the program SAINT12 for all data-collections performed on the 
Nonius Kappa CCD diffractometer. Intensity data collected on the Bruker Apex II 
used the program SAINT12 for unit cell refinement and data reduction. All intensity 
data were corrected for Lorentz-polarisation effects. The X-ray diffraction data 
obtained from crystals containing heavy atoms such as sulfur, phosphorus and 
chlorine were corrected for absorption using the program SADABS.13 The crystal 
system was established from the observed Laue symmetry of the diffraction pattern 
and the space group was determined by examining systematic absences and 
matching the observed conditions to a known space group. The input files for 
structure solution were prepared using the program XPREP.14 All crystal structures 
were solved by direct methods using SHELXS-9715 and refined by full-matrix least-




The SHELXH-9715 software program uses full-matrix least-squares fitting to minimize 
the value of ∑ 𝑤(𝐹o2 − 𝐹c2)2  i.e. the sum of the squares of the differences between 
the observed and calculated intensities. The agreement between the observed (𝐹o) 
and calculated (𝐹c) structure factors is expressed by the residual index R1, where a 
low R1 value indicates a good model (1). A second residual index, wR2, indicates the 
agreement between the observed and calculated intensities for the refinement 
against 𝐹2 (2). 
 
𝑅1 =  
∑||𝐹o|−|𝐹c||
∑|𝐹o|
  (1) 







The weighting scheme, 𝑤, used in (2) as well as the parameters 𝑎 and 𝑏 were 
refined for each structure using expressions (3) and (4) below. The value 𝑆 (also 
referred to as the “Goodness of Fit” parameter) is defined in expression (5), with 𝑛 
equal to the number of reflections and 𝑝 the total number of parameters. A well-
refined structure will have 𝑆 close to unity and a 𝑛/𝑝 ratio close to 10.  
 





                                                𝑤 =  [𝜎2(𝐹o2)  + (𝑎𝑃)2 + 𝑏𝑃]-1    (3)       
       
                   𝑃 =  
max(0,𝐹o2) +2𝐹c2
3
                       (4) 
 





2                        (5) 
 
The program PLATON17 was used to calculate intramolecular and intermolecular 
geometrical parameters as well as the standard deviations for these values. Images 
of the crystal structures were created with POV-Ray for Windows.18 The program 
LAYER19 was used for the graphic display of intensity data as simulated precession 
photographs and this was useful when assigning space groups. The final 
crystallographic data files for each crystal structure described in this dissertation can 
be found in the Appendix. Table 1 lists the file types and information they contain. 
 
Table 1: Crystallographic data files that can be found in the Appendix.  
Extension Details 
.hkl Reflection data 
.res SHELX co-ordinate data 
.cif Crystallographic information 
.fcf Observed and calculated intensities 
.lis Platon output 
.xl SHELX output 
.sup Tabulated supplementary data 
 
Solubility studies  
 
For phase solubility and equilibrium solubility studies, UV-visible spectroscopy was 
used to determine the concentration of the drug lead present in solution. Using the 
Beer-Lambert law (6) as it applies to the relationship between absorbance and 
concentration, it was possible to quantify the amount of the drug lead present in a 
given solution.  
 




Expression (6) describes a linear relationship between the absorbance (A) and 
concentration (c) of an absorbing species with a constant path length (l) and 
extinction co-efficient (εo).   
 
A = εocl    (6)  
 
Calibration curves for the drug leads were constructed by preparing a stock solution 
of known concentration and then preparing solutions of varying concentrations from 
the stock solution. Due to the poor aqueous solubility of the drug leads a small, 
known amount of ethanol was added to the aqueous solutions to facilitate drug 
dissolution. All of the phase solubility and equilibrium solubility experiments were 
performed in a 1% ethanol/water [v/v] medium. The absorbance readings of the 
solutions were plotted against the molar concentration of the drug lead to obtain the 
calibration curve. The absorbance readings were recorded on a Cintra 20 UV-visible 
spectrometer and data were processed using the GBC Spectral computer program 
(v1.70, December 1998).  
 
Equilibrium solubility studies 
 
The equilibrium solubility of the drug leads, co-crystals or salts were determined by 
adding an excess amount of the material to 5 cm3 of a 1% ethanol/water [v/v] 
solution in a polytop vial. The vial was capped and placed on a temperature 
controlled carousel and the solution was stirred at 500 rpm for 72 hours at              
25 ± 0.5 °C.  The solution was filtered through a 0.45 μm nylon filter and diluted 
appropriately before the UV spectrum was recorded. The concentration of the drug 
lead was determined from the respective calibration curve obtained as described 
above.   
 
Phase solubility studies  
 
Phase solubility studies were carried out by preparing serial dilutions of a 
cyclodextrin solution and adding excess amounts of the drug lead to each solution. 
An excess amount of the drug lead was added to a polytop vial containing 5 cm3 of 
the cyclodextrin solution. The vials were capped and placed on a temperature 




controlled carousel and stirred (500 rpm) at constant temperature (25 ± 0.5 °C) for 
72 hours. The solutions were filtered through a 0.45 μm nylon filter and diluted 
appropriately before the UV-visible spectrum was recorded. The concentration of the 
drug lead was determined from the respective calibration curve obtained as 
described above. 
 
Turbidimetric solubility assay 
 
The aqueous solubility of the solvated adipic acid-DL4 salt was assessed using a 
turbidimetric solubility assay. This was performed by dissolving crystals of the salt in 
DMSO and then adding aliquots of the DMSO solution to 0.01M pH 7.4 Phosphate 
Buffered Saline (PBS) to obtain serial dilutions in a 96 well plate. Serial dilutions of 
DL4, the solvated adipic acid salt of DL4 (DL4ADI), reserpine and hydrocortisone 
were prepared in triplicate. Reserpine and hydrocortisone are standards of known 
solubility in the solvent medium. After preparing the serial dilutions the solutions 
were left to equilibrate for 2 hours. The approximate solubility of the salt was 
determined to be the concentration above which precipitation occurs, causing the 
solution to become turbid. The UV-visible absorbance of the solutions was recorded 
at 620 nm, because most compounds are not expected to absorb at this wavelength 
so any absorbance that was detected would be due to particles in solution. UV-
visible spectra were recorded using a Molecular Devices SpectraMax 340PC 96 well 
plate reader and the data were analysed using the SoftMaxPro software package 
(v5.4.1).20-24 
 
In vivo testing  
 
An inclusion complex prepared during this study was submitted for in vivo biological 
testing to establish whether it showed any improved biological activity compared to 
the parent compound (drug lead).   
 
In vivo pharmacokinetic testing  
 
In vivo pharmacokinetic testing was carried out by Dr Natasha Strydom and 
colleagues from the Department of Pharmacology at the University of Cape Town 
(South Africa). Nine 6-week-old C57BL/6 mice were divided into an intravenous and 




two oral dosage groups (n = 3). For the intravenous group, a single 2.5 mg/kg dose 
(formulation: DMSO, PEG, EtOH, PPG [2:6:1:7, v/v]) was injected into the penile 
dorsal vein. 20 µl of blood was collected from the tail tip at 0.08, 0.5, 1, 3, 8 and 24 
hours and stored at - 80°C. Oral dosing was achieved using a single Torpac® 
capsule containing 5 mg kg-1 equivalent active dose of either the inclusion complex 
or the drug for oral groups A and B respectively. Blood samples were collected at 
0.5, 1, 3, 5, 8 and 24 hours and stored at - 80°C for analysis.25  
 
Whole blood concentration of the drug lead was quantified by an LC-MS/MS assay 
developed for a range of 2 – 3000 ng cm-3. The samples were extracted by protein 
precipitation using 20 µl of whole blood and a 240 µl acetonitrile precipitation solution 
containing two internal standards. Samples were vortexed for 1 minute and 
centrifuged at 10 000 G for 5 minutes. For analysis 200 µl of the supernatant was 
collected, dried and reconstituted using a 100 µl 0.1% formic acid in 
acetonitrile/water [1:1, v/v] injection solution. Gradient chromatography was 
performed on a Phenomenex Kinetix PFP (2.1 × 50 mm, 2.4 µm) reverse phase 
column with mobile phase 0.1% formic acid in water [v/v] and 0.1% formic acid in 
acetonitrile at a flow rate of 200 µl min-1. An AB Sciex API 4000Q mass spectrometer 
was operated at unit resolution in multiple reaction monitoring mode to monitor the 
transitions of the protonated molecular ions to their product ions for the compound of 
interest, i.e. 355.8 → 277.0 m/z. Non-compartmental analysis was performed using 
Summit PK solutions™ (Summit Research Services, Montrose, USA).25 
 
In vivo efficacy testing 
 
In vivo efficacy testing was carried out by Dr Sergio Wittlin and colleagues at the 
Swiss Tropical and Public Health Institute (Basel, Switzerland) according to the 
methodology described by Le Manach et al.26 Mice (n = 3) were infected with a GFP-
transfected P. berghei ANKA strain of malaria and parasitemia was determined using 
standard flow cytometry techniques with a detection limit of 0.1% (1 parasite in 1000 
erythrocytes). The activity of the drug lead or inclusion complex was calculated as 
the difference between the mean percentage parasitemia for the control and treated 
groups expressed as a percentage relative to the control group. Compounds were 
suspended in a 4% Tween80 and 9% ethanol [v/v] suspension vehicle and orally 




administered once per day on four consecutive days (4, 24, 48, and 72 h after 
infection). Blood samples were collected after 96 hours. 
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CHAPTER 3: Solid-state chemistry of ethyl 7-amino-2-
benzyl-4-methyl-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-
c]pyridine-6-carboxylate (DL2): a novel anti-tubercular 




At the start of the project, the UCT Drug Discovery and Development Centre, H3D, 
provided an anti-tubercular compound for supramolecular derivatisation, namely               
6-(methyl-4-(trifluoromethyl)benzylamino)-N-phenylpyrimidine-4-carboxamide seen 
in Figure 1. This compound will be referred to as DL1 (drug lead 1) henceforth. DL1 
was recrystallized from a variety of solvents using different crystallization techniques, 
but unfortunately none of the experiments yielded any single crystals and the crystal 
structure for this compound has not yet been elucidated. Liquid-assisted grinding 
experiments were performed with DL1 and a range of co-crystal formers as part of a 
co-crystal screening and the results indicated that all of the experiments produced 
only physical mixtures of DL1 and the co-crystal former. Attempts to include DL1 in 
both native and derivatised cyclodextrins were all unsuccessful except in the case of 
the kneading experiment with γ-cyclodextrin and DL1. The results of all the 
experiments carried out with DL1 can be found in the Appendix. DL1 was 
recrystallized from eight solvents, co-crystal screening was carried out using twelve 
co-formers and CD inclusion was attempted using the native CDs as well as three 
derivatised CDs. At first glance the experiments with DL1 appear to have been 
unsuccessful. However, from a drug discovery and design perspective these results 
highlight a very important concept. They demonstrate the ability of early 
supramolecular intervention to streamline this process. They also provide valuable 
information about which compounds are amenable to beneficiation via 
supramolecular modification, ultimately reducing wasted time, effort and money 




Figure 1: Molecular structure of DL1. 
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The drug lead that will be the focus of this chapter is ethyl 7-amino-2-benzyl-4-
methyl-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-6-carboxylate (Figure 2) 
which  will be referred to as DL2 henceforth. The X-ray crystal structure of DL2 has 
been solved and will be discussed in this chapter. Co-crystal screening and CD 









NMR and Mass Spectroscopy 
 
The 1H NMR and the LC-MS spectra for DL2 were provided by the H3D Centre and 






Crystals of DL2 were heated at a rate of 10 K min-1 during a HSM experiment and 
the representative HSM photographs are shown in Figure 3. The photograph taken 
at 184 °C shows the crystals starting to melt and the entire sample has melted at  
194 °C. Following melting, the vapour condensed onto the top glass cover slide of 






 25 °C 157 °C 184 °C 194 °C 
Figure 3: Representative HSM photographs of DL2 
Figure 2: Molecular structure of DL2. 
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TGA and DSC 
 
The DSC trace of DL2 (Figure 4) shows the onset of melting occurring at 187 °C 
followed by a sharp endothermic peak corresponding to the melting point at 188 °C, 
with ΔHfus = 37.37 kJ mol-1. 
 
The TGA trace in Figure  5 shows no significant mass loss until 228 °C when the 
melt vaporizes.  
 
Figure 4: DSC trace for DL2 
 
 
Figure 5: TGA trace for DL2 
 
Preparation of single crystals 
 
The recrystallization of DL2 was performed by dissolving 10 mg (0.03 mmol) of DL2 
in approximately 1 cm3 of acetone. The solution was gently heated to 40 °C while 
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stirring and then filtered through a 0.45 μm nylon filter into a clean vial and left to 
crystallize under ambient conditions. Crystals were obtained after 24 hours.  
 
Crystal structure analysis 
 
Data-collection and space group determination 
 
Crystal intensity data were collected on a Bruker KAPPA APEX II DUO single crystal 
X-ray diffractometer. The data were corrected for absorption using the program 
SADABS.1 The Laue symmetry was found to be 2/m indicating the monoclinic crystal 
system and the space group P21/n (an alternative setting of the space group P21/c) 
was identified from systematic absences. The crystal system and space group were 
subsequently confirmed by the program XPREP.2  
 
Structure solution and refinement 
 
Crystal and refinement data for DL2 are shown in Table 1 below. The unit cell 
refinement and data reduction were performed using the program SAINT.3 After 
solving the structure using SHELXS-974 all of the non-hydrogen atoms were 
revealed. The non-hydrogen atoms were placed and refined isotropically using 
SHELXH-97.4 None of the atoms displayed any disorder after being refined 
isotropically and subsequently they were all refined anisotropically. All of the 
hydrogen atoms were placed in idealised positions based on a riding model and 
were refined isotropically. The methylene and phenyl hydrogens were refined with 
Uiso values 1.5 times those of the carbon atoms to which they were attached. Methyl 
hydrogens were refined with Uiso values 1.2 times those of the parent atoms. The 
methyl hydrogens attached to C18 were found to be disordered over two positions 
and they were placed in idealised positions using an appropriate model. The 
hydrogens of the amine group appeared in difference Fourier maps and after the 
planar geometry of the NH2 group was confirmed, they were allowed to refine freely.  
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Table 1: Data-collection and refinement parameters for DL2 
Chemical Formula  C18H17N3O4 
Formula weight (g mol-1)  339.35 
Crystal system  Monoclinic 
Space group  P21/n 
a (Å)  4.774(2) 
b (Å)  23.752(1) 
c (Å)  14.869(8) 
α (°)            90 
β (°)  94.245(1) 
γ (°) 90 
V (Å3)  1681.5(2) 
Z  4 
Dc (g cm-3)  1.340 
μ (Mo Kα) (mm-1)  0.097 
F(000)  712 
Data collection temp. (K) 173(2) 
Crystal size (mm3)  0.06  0.11  0.60 
Range scanned θ (°)  1.6 - 27.6 
Index ranges ±h, ±k, ±l h: -5, 6; k: -30, 30; k: -19, 19 
Reflections (total) 18786 
Independent reflections  3846 
Reflections with I>2σ(I)  1818 
No. of parameters 233 
Rint  0.044 
Goodness-of-fit, S 1.00 
R1 [I>2σ(I)]  0.0559 
Reflections omitted 1 
wR2 0.1741 
Parameters a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] 0.0662, 0.4388 
(Δ/σ)mean  < 0.001 
Δρmin, max (e Å-3)  -0.17, 0.31 
 
Molecular structure  
 
Figure 6 shows a diagram of the DL2 molecule with the labelling scheme. The fused 
pyridine-pyrrolidine ring system is planar with a maximum deviation of 0.008(2) Å 
from the least-squares plane (C9). The C-C bond lengths in the pyridine-pyrrolidine 
ring system range between 1.379(2) Å and 1.486(4) Å and the angles range between 
105.9(2)° and 124.0(2)°. The phenyl ring is also planar with a maximum deviation of 
0.008(4) Å from the least-squares plane (C22). The C-C bond lengths in the phenyl 
ring range between 1.336(4) Å and 1.413(6) Å and the angles range between 
118.2(4)° and 122.0(4)°. The two torsion angles C2-N1-C19-C20 and N1-C19-C20-
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C25 are 111.2(3) and 129.1(3)° respectively, defining the orientation of the phenyl 
ring with respect to the fused system. The chain of atoms C14-C17 is in an extended 
conformation. The three C=O carbonyl bond lengths range between 1.202(4) Å and 




Hydrogen bonding  
 
There are two intramolecular hydrogen bonds of type N-H•••O, namely                        
N12-H12A•••O10 and N12-H12B•••O18. There are also two intramolecular hydrogen 
bonds of type C-H•••O, namely C13-H13D•••O11 and C19-H19A•••O11. An 
intermolecular hydrogen bond, N12-H12A•••O10a (a = 2-x, -y, 2-z) is also present. 
The molecules of DL2 form centrosymmetric hydrogen bonded dimers via two 
inversion-related N12-H12A•••O10 hydrogen bonds. The intermolecular                       
N12-H12A•••O10 hydrogen bonds generate a 𝑅22(12) hydrogen bonding motif 
(Figure 7). 
 
Table 2: Hydrogen bonding interactions for DL2. 
Interaction D-H (Å) H•••A (Å) D•••A (Å) D-H•••A (°) 
Intramolecular 
N12-H12A•••O10 0.96(4) 2.35(3) 3.024(4) 127(2) 
N12-H12B•••O18 0.87(3) 2.00(3) 2.691(4) 136(3) 
C13-H13D•••O11 0.98 2.48 3.226(4) 132 
C19-H19A•••O11 0.99 2.55 2.919(4) 102 
Intermolecular 
N12-H12A•••O10a 0.96(4) 2.17(3) 3.009(4) 145(2) 
Symmetry codes: a 2-x, -y, 2-z 
Figure 6: Molecular structure of DL2 showing thermal ellipsoids at the 50% probability level. 








The centrosymmetric hydrogen bonded dimers are co-planar, resulting in a layered 
packing arrangement of the DL2 molecules. This can be seen very clearly when the 
structure is viewed down the b-axis (Figure 8). The program Mercury5 was used to 
calculate the least-squares plane through two adjacent layers and the distance 
between the two planes was found to be 3.567 Å. This distance corresponds with the 
interplanar distance d1 0 -3 = 3.564 Å, resulting in an intense peak at 2θ position 
24.99° in the PXRD trace for DL2 (Figure 9).  
 
 
Figure 8: Crystal packing projected along [010] (hydrogens have been omitted for clarity). 
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Comparative PXRD  
 
The calculated and experimental PXRD traces for DL2 are shown in Figure 9. The 
two patterns are practically indistinguishable and this high level of agreement 





Co-crystal screening  
 
The Cambridge Structural Database (CSD)6 was searched for co-crystals or salts 
that contained similar functional groups to those in DL2. The results of the search 
were used as a guideline for the selection of the co-formers that were used in the co-
crystal screening with DL2. The CSD was searched for common supramolecular 
synthons such as the ones shown in Figure 10. The results showed that the 
functional groups that were most likely to form supramolecular synthons with DL2 
were the carboxylic acid (35 hits) and amide (36 hits) functional groups. Nine             
co-formers that contained the necessary functionalities were selected for co-crystal 




Figure 9: Calculated and experimental PXRD traces for DL2. 






The first stage of the co-crystal screening involved dry co-grinding with the co-former 
and DL2 and the results are summarised in Table 3. Dry co-grinding experiments 
were carried out as described in the previous chapter. The products were analysed 
by PXRD and the results indicated that all of the experiments resulted in physical 
mixtures of the two components.  Figure 11 has been included as a representative 
PXRD trace to illustrate that the PXRD trace of the product was clearly a 
combination of the PXRD traces for the separate components and it was therefore 
concluded that no new phase had emerged as a result of the dry co-grinding 
experiments. All of the PXRD traces for the dry co-grinding experiments have been 
included in the Appendix.   
 
Table 3: Summary of experimental outcomes for the dry co-grinding stage of co-crystal screening with 
DL2 
Co-former Molar ratio Outcome 
Adipic acid 1:1 Physical mixture 
L-ascorbic acid 1:1 Physical mixture 
Citric acid 1:1 Physical mixture 
L-malic acid 1:1 Physical mixture 
Fumaric acid 1:1 Results pending 
Nicotinamide 1:1 Physical mixture 
Propionamide 1:1 Physical mixture 
Benzamide 1:1 Physical mixture 
Uracil 1:1 Physical mixture 
 
Figure 10: Supramolecular synthons that occur in the CSD. 




Figure 11: PXRD traces for DL2, propionamide and the product of the dry co-grinding experiment. 
 
The next stage of the co-crystal screening involved liquid-assisted grinding (LAG) 
experiments. The co-former was ground for 15 minutes with DL2 while small drops of 
ethanol or acetonitrile were added. Ethanol was used as the solvent during LAG, 
because it appears on the FDA GRAS database.7 The products of the LAG 
experiments were analysed by PXRD and the results (Table 4) indicated that all of 
the experiments resulted in only physical mixtures of DL2 and the co-former. The 
PXRD traces from the LAG experiments have been included in the Appendix.  
 
Table 4: Summary of experimental outcomes for the liquid-assisted grinding stage of co-crystal 
screening with DL2. 
Co-former Solvent  Molar ratio Product 
Adipic acid Ethanol 1:1 Physical mixture 
L-ascorbic acid Ethanol 1:1 Physical mixture 
Citric acid Acetonitrile 1:1 Physical mixture 
L-malic acid Ethanol 1:1 Physical mixture 
Fumaric acid Ethanol 1:1 Physical mixture 
Nicotinamide Ethanol 1:1 Physical mixture 
Propionamide Ethanol 1:1 Physical mixture 
Benzamide Ethanol 1:1 Physical mixture 
Uracil Ethanol 1:1 Physical mixture 
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The products of the LAG experiments were recovered after PXRD analysis and 
recrystallized from acetone. The unit cells of single crystals that resulted from the 
recrystallization were checked and in all of the cases DL2 crystallized separately 




Kneading and co-precipitation experiments were carried out in an attempt to include 
DL2 in CDs. In the case of the kneading experiments, DL2 and each of the native 
CDs were kneaded for 20 minutes while adding small drops of Milli-Q8 water. The 
products were analysed using PXRD and the results are summarised in Table 5. The 
PXRD traces of the products indicated that all of the kneading experiments resulted 
in a physical mixture of DL2 and the CD. Figure 12 has been included as a 
representative PXRD trace for the kneading experiments. All of the PXRD traces 
from the CD experiments can be found in the Appendix.  
 
Table 5: Kneading experiments with DL2. 
CD Solvent Molar ratio Method Product 
α-CD H2O 1:1 20 min kneading Physical mixture 
β-CD H2O 1:1 20 min kneading Physical mixture 
γ-CD H2O 1:1 20 min kneading Physical mixture 
 
 
Figure 12: PXRD trace for α-CD, DL2 and the product of kneading DL2 and α-CD. 
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Co-precipitation experiments with DL2 and the native CDs as well as           
heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB), heptakis(2,3,6-tri-O-methly)-β-
cyclodextrin (TRIMEB) and hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin (TRIMEA) 
were unsuccessful. For co-precipitation with the native CDs, DL2 was added to a hot        
(50 °C) aqueous solution of the CD and ethanol was added to aid the dissolution of 
DL2. The solution was stirred for approximately 24 hours and then filtered. For the 
derivatised CDs, DL2 was dissolved separately in either ethanol or acetone and then 
added to an aqueous solution of the CD at room temperature. After filtering, the 
solution was placed in an oven at 60 °C. None of these experiments yielded any CD 
inclusion complexes.  
 
Table 6: Co-precipitation experiments with selected CDs and DL2. 
CD Solvent Molar ratio Method Product 
α-CD H2O/Ethanol 1:1 Slow cooling from 50 °C No  complex 
β-CD H2O/Ethanol 1:1 Slow cooling from 50 °C No  complex 
γ-CD H2O/Ethanol 1:1 Slow cooling from 50 °C No  complex 
DIMEB H2O/Ethanol 1:1 Recrystallization at 60 °C No  complex 
DIMEB H2O/Acetone 1:1 Recrystallization at 60 °C No  complex 
TRIMEB H2O/Ethanol 1:1 Recrystallization at 60 °C No  complex 
TRIMEB H2O/Acetone 1:1 Recrystallization at 60 °C No  complex 
TRIMEA H2O/Ethanol 1:1 Recrystallization at 60 °C No  complex 
TRIMEA H2O/Acetone 1:1 Recrystallization at 60 °C No  complex 
 
None of the desired products (co-crystals or inclusion complexes) were produced 
and the results indicate that DL2 may not be a favourable candidate for further drug 
development. In retrospect, the poor solubility could be explained by examining the 
crystal structure of DL2. Both of the hydrogens in the amine group are involved in 
intramolecular hydrogen bonding with the adjacent carbonyl oxygens. The third 
carbonyl oxygen is also involved in intramolecular hydrogen bonding with the 
adjacent methyl group. This suggests that the preferred configuration of the molecule 
is to have C19-H19B and the C14-C17 chain in positions that facilitate intramolecular 
hydrogen bonding with the fused pyridine-pyrrolidine ring system. It appears that 
these strong intramolecular and intermolecular hydrogen bonding systems in DL2 
could preclude its ability to form new hydrogen bonds with other molecules.  
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Another observation was that DL2 displayed very poor solubility in both aqueous and 
organic media. The poor solubility of DL2 can present challenges not only in terms of 
bioavailability in vivo, but also for biological testing. If DL2 cannot be solubilized 
enough in aqueous media, it will be extremely difficult to accumulate relevant 
biological data for this drug lead.  Therefore, an alternative approach will be required 
to improve the aqueous solubility. One alternative approach is the use of CDs to 
improve aqueous solubility of poorly soluble compounds. This approach will be 
explored in the next chapter, which will discuss the phase solubility studies that were 
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CHAPTER 4: Phase solubility studies with 7-amino-2-(3-
chlorobenzyl)-4-methyl-6-(3-methyl-1,2,4-oxadiazol-5-yl)-
1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione (DL3): a novel anti-





[3,4-c]pyridine-1,3(2H)-dione, (‘DL3’ henceforth), is an analogue of DL2, which was 
discussed in Chapter 3. These compounds are part of a novel series of                 
anti-tubercular compounds identified by the H3D centre in collaboration with the 
Novartis Institute for Tropical Disease (NITD). DL2 was identified as a “hit” 
compound from a high-throughput screening conducted by NITD and was further 
optimized to obtain DL3. Both drug leads contain a fused pyridine-pyrrolidine ring 
system (Figure 1). As discussed in the previous chapter, DL2 displayed poor 
solubility in both organic and aqueous media and the same observation was made 
for DL3. It was therefore necessary to explore alternative ways of enhancing the 
solubility of DL3. One such approach is cyclodextrin (CD) inclusion, which has been 
shown to significantly improve the solubility of poorly soluble compounds.1 This 
chapter will discuss the phase solubility studies performed with DL3 and various 
CDs. The crystal structure of DL3 was successfully elucidated and will also be 
presented.  
 
Figure 1: Structures of DL2 and DL3. 
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NMR and mass spectroscopy 
 
The 1H, 13C NMR and LC-MS spectra for DL3 were provided by the H3D Centre and 






Crystals of DL3 were heated at a rate of 10 K min-1 during a HSM experiment and 
the representative HSM photographs are shown in Figure 2. The crystals of DL3 
start to melt at 191 °C and the entire sample is molten at 199 °C. No other significant 
thermal events were observed.  
 
 
Figure 2: Representative HSM photographs of DL3. 
 
TGA and DSC  
 
The TGA trace of DL3 (Figure 3) shows no significant thermal events occurring 
before the onset of decomposition at 197 °C.  
 




Figure 3: TGA trace for DL3. 
 
The baseline of the DSC trace for DL3 (Figure 4) is sloped and this is most probably 
due to some irregularity with the DSC instrument at the time of recording. However, it 
is still possible to observe the endotherm (ΔHfus = 18.20 kJ mol-1) corresponding to 
the fusion of DL3, spanning the range 185 °C to 198 °C (peak at 187 °C).  
 
 
Figure 4: DSC trace for DL3. 
 
Preparation of single crystals  
 
Single crystals were obtained from the recrystallization of DL2. 10 mg of DL2 was 
dissolved in approximately 1 cm3 acetone and gently heated to 40 °C while stirring. 
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The solution was filtered through a 0.45 μm nylon filter into a clean vial and left to 
crystallize under ambient conditions. Yellow plate-like crystals were obtained after 48 
hours.  
 
Crystal structure analysis  
 
Data-collection and space group determination 
 
Crystal intensity data for DL2 were collected on a Nonius KappaCCD single crystal 
X-ray diffractometer and corrected for absorption effects using the program 
SADABS.2 Unit cell refinement and data reduction were performed using the 
programs DENZO and SCALEPACK.3 The space group and crystal system of DL3 
were determined using the program LAYER.4 The Laue symmetry was found to be   
1 indicating the triclinic crystal system and the mean E2 -1 parameter value of 
0.956 obtained using the program XPREP5 identified the space group as P1.  
 
Structure solution and refinement 
 
Table 1 contains the crystal and refinement data for DL3. The structure was solved 
by direct methods using SHELXS-97,6 which revealed all of the non-hydrogen 
atoms. The non-hydrogen atoms were placed and refined first isotropically and then 
anisotropically using SHELXH-97.6 After confirming the planar geometry of both 
amino groups in the asymmetric unit, all of the hydrogen atoms were placed in 
idealised positions based on a riding model and were refined isotropically with Uiso 
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Table 1: Data-collection and refinement parameters for DL3. 
Chemical Formula  C18H14N5O3Cl 
Formula weight (g mol-1)  383.79 
Crystal system  Triclinic 
Space group  P1 
a (Å)  7.7740(3) 
b (Å)  14.8745(8) 
c (Å)  15.4291(8) 
α (°)            102.988(2)  
β (°)  91.816(3)  
γ (°) 98.091(3) 
V (Å)3 1717.5(2) 
Z  4 
Dc (g cm-3)  1.484 
μ (Mo Kα) (mm-1)  0.254 
F(000)  792 
Data collection temp. (K) 173(2) 
Crystal size (mm3)  0.03  0.09  0.45 
Range scanned θ (°)  2.8 - 26.7 
Index ranges ±h, ±k, ±l h: -9, 9; k: -18, 18; k: -19, 19 
Reflections (total) 39818 
Independent reflections  7239 
Reflections with I>2σ(I)  4931 
No. of parameters 491 
Rint  0.053 
S 1.02 
R1 [I>2σ(I)]  0.0434 
Reflections omitted 35  
wR2 0.1115 
Parameters a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] 0.0536, 0.4213 
(Δ/σ)mean  <0.001  
Δρmin, max (e Å-3)  -0.29, 0.25 
 
Molecular structure  
 
Figure 5 shows the asymmetric unit of DL3 with the labelling scheme. The 
asymmetric unit consists of two molecules of DL3 which have been labelled A and B. 
The fused pyridine-pyrrolidine ring system in molecule A is planar with a maximum 
deviation of 0.025(2) Å from the least-squares plane (C5A). The angle between the 
fused pyridine-pyrrolidine ring system and the oxadiazole ring is 0.53(8)°. The 
orientation of the phenyl ring with respect to the fused ring system is defined by the 
two torsion angles C2A-N1A-C20A-C21A and N1A-C20A-C21A-C26A and these are 
-103.5(2)° and 94.9(2)° respectively. In molecule B the fused pyridine-pyrrolidine ring 
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system is also planar with a maximum deviation of 0.023(2) Å from the least-squares 
plane (C4B) and the angle between this ring system and the oxadiazole ring is 
4.09(9)°. The torsion angles C2B-N1B-C20B-C21B (-103.2(2)°) and N1B-C20B-
C21B-C26B (96.4(2)°) define the orientation of the phenyl ring with respect to the 
fused ring system. All geometrical data can be found in the Appendix.  
 
Figure 5: The asymmetric unit of DL3 showing thermal ellipsoids at the 50% probability level. 
 
Hydrogen bonding and crystal packing  
 
The hydrogen bonding interactions between molecules A and B are generated by 
two intramolecular (C13B-H13E•••O11B and N12A-H12A•••O10A) and two 
intermolecular (C13B-H13E•••O10A and N12A-H12A•••O11B) hydrogen bonds. 
These four bonds form a cyclic (quadrilateral) motif. There are also two 
intermolecular hydrogen bonding interactions, N12A-H12A•••O11B and C13B-
H13E•••O10A, that propagate the quadrilateral hydrogen bonding motif parallel to the 
c-axis (Figure 6). The hydrogen bonding interactions are listed in Table 2.  
  




Figure 6: Hydrogen bonding interactions in DL3 viewed along [1 0 0]. 
 
Table 2: Hydrogen bonding interactions for DL3. 
Interaction D-H (Å) H•••A (Å) D•••A (Å) D-H•••A (°) 
Intramolecular 
N12A-H12A•••O10A 0.88 2.43 3.043(2) 127 
N12B-H12C•••O10B  0.88 2.42 3.036(2) 128 
N12A-H12B•••N18A  0.88 2.09 2.750(2) 131 
N12B-H12D•••N18B 0.88 2.09 2.752(2) 131 
C13A-H13B•••O11A 0.98 2.50 3.216(3) 129 
C13B-H13E•••O11B 0.98 2.53 3.227(3) 128 
Intermolecular 
N12B-H12D•••O11Aa 0.88 2.15 2.824(2) 133 
C13A-H13B•••O10Bb 0.98 2.54 3.355(3) 141 
C13B-H13E•••O10A 0.98 2.54 3.328(2) 138 
N12A-H12A•••O11B 0.88 2.15 2.809(2) 131 
C19A-H19C•••N7Bc 0.98 2.60 3.401(3) 139 
a x, y, -1+z; b x, y, 1+z; c 2-x, 1-y, 1-z 
 
DL3 has a layered packing arrangement and there is a weak C19A-H19C•••N7Bc       
(c = 2-x, 1-y, 1-z) between the layers (Figure 7). The layers lie very close to the            
(23 0) planes, resulting in an intense peak at the 2θ-angle 27.51° in the PXRD trace 






















Figure 7: Packing diagram of DL3 viewed along [0 1 0]. The left image shows the weak C19A-H19C•••N7Bc 
hydrogen bonding interactions between the layers of DL3 molecules. The right image shows a space-
filling view of the layers.  
 
Comparative PXRD  
 
The experimental and calculated PXRD traces for DL3 are shown in Figure 8. There 
is a high level of agreement between the experimental and the calculated traces 
which confirms that the single crystal is representative of the bulk material. 
 
Figure 8: Experimental and calculated PXRD traces for DL3. 
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Phase solubility studies 
 
Phase solubility studies were carried out with DL3 and seven different CDs: β-CD, 
hydroxypropyl-β-CD (HPβCD), β-CD polymer, γ-CD, hydroxypropyl-γ-CD (HPγCD), 
γ-CD polymer and randomly methylated β-CD (RAMEB) in an attempt to enhance its 
poor aqueous solubility (3.84 mg cm-3, equivalent to 0.01 mM at 25 °C). 
 
The phase solubility experiments were performed according to the method described 
by Higuchi and Connors.8 Serial dilutions of each CD solution were prepared and an 
excess amount of DL3 was added to a polytop vial containing 5 cm3 of each solution. 
The vials were stirred (500 rpm) at constant temperature (25 ± 0.5 °C) for 72 hours. 
The solutions were filtered through a 0.45 μm nylon filter and their UV-visible spectra 
were recorded. The concentration of DL3 was determined from a calibration curve 




Figure 9: Calibration curve for DL3. 
 
Expression (1) describes a linear relationship between the absorbance (A) and 
concentration (c) of an absorbing species with a constant path length (l) and 
extinction co-efficient (εo). Using equation (1) the extinction coefficient (εo) of DL3 
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was found to be 0.0205 mM-1 cm-1, indicating that the compound is not particularly 
UV active. Any absorbance measurements that fell within the error of the instrument 
(less than 0.01 absorbance units) were not reported, because they were considered 
to be unreliable. Each CD solution containing DL3 was filtered directly into the 
cuvette before the UV spectrum was recorded. The solutions were not diluted and 
therefore the phase solubility profiles were constructed based on single 
measurements. This was done to ensure that the solution in the cuvette contained a 
maximum concentration of DL3 and that the resulting absorbance measurements 
were reliable i.e. at least 0.01 absorbance units.  
 
A = εocl    (1)  
 
The results of the phase solubility studies performed with γ-CD, hydroxypropyl γ-CD 
(HPγCD) and γ-CD polymer are not reported, because the UV measurements 
recorded during the experiments were unreliable (the values recorded for the UV-
visible spectra were less than 0.01 absorbance units). Phase solubility studies with 
DL3 and RAMEB produced erratic results and these results have also been 
excluded.  
 
Higuchi and Connors classified phase solubility profiles as either A- or B-type.8             
A-type behaviour is consistent with an increase in solubility of the compound with an 
increase in CD concentration. There are three sub-types of A-type behaviour: AL-
type curves show a linear increase in solubility with increasing CD concentration, 
whereas AP- and AN-type curves display a positive or negative deviation respectively 
due to a change in the physical nature of the solution. B-type behaviour indicates the 
formation of an insoluble complex in solution. The subtype BS indicates the formation 
of an insoluble complex with limited solubility, while BL indicates the formation of an 
insoluble complex.8 
 
The phase solubility profile for β-CD (Figure 10) can be classified as AP-type. This is 
due to the approximately linear increase in the apparent solubility of DL3 up to a β-
CD concentration of 12 mM, after which there is a positive deviation. At the highest 
concentration of β-CD used the apparent solubility of DL3 increased to 3.6 mM, i.e. 
representing a solubility enhancement of 360-fold. It was not possible to quantify the 
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concentration of DL3 that was solubilized by a 20 mM β-CD solution, because the 
complex precipitated from the solution after only 24 hours. This can be attributed to 
the aggregation of β-CD molecules at this higher concentration.  
 
 
Figure 10: Solubility of DL3 as a function of [β-CD] at 25°C. 
 
Figure 11 shows the phase solubility profile using HPβCD as host. There is a linear 
relationship between the concentration of DL3 and HPβCD concentration and this 
behaviour is classified as AL-type. At the highest concentration of HPβCD used the 
apparent solubility of DL3 increased by a factor of more than 400.  
    
 
Figure 11: Solubility of DL3 as a function of [HPβCD] at 25°C. 
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The association constants for complex formation were calculated using Equation (2), 
where 𝑆0 is the intrinsic solubility of DL3 at 25 °C and “slope” is the slope of the 
phase solubility profile. This equation is only valid for 1:1 host-guest complexes with 
the slope of the plot being less than 1. The initial slope of the β-CD profile was used 
to calculate 𝐾C. The estimated apparent stability constants for complex formation 
with β-CD and HPβCD were found to be 14 700 M-1 and 26 780 M-1 respectively. 






                   (2) 
 
The results from the phase solubility studies demonstrate very clearly that it was 
possible to achieve a significant enhancement in the solubility of DL3 through the 
use of CDs. This result is also important in that it could have applications for drug 
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CHAPTER 5: Co-crystal screening with 3-(6-methoxy- 
pyridin-3-yl)-5-(4-methylsulfonylphenyl)-pyridin-2-amine 




3-(6-Methoxypyridin-3-yl)-5-(4-methylsulfonylphenyl)-pyridin-2-amine (DL4, Figure 1) 
is a novel antimalarial drug lead that has been reported in the literature.1  DL4 
displayed potent in vitro antiplasmodial activity against both the K1 (multi-drug 
resistant) and NF54 (sensitive) strains of the human malaria parasite Plasmodium 
falciparum, with an IC50 value of 0.051 μM for both strains. DL4 also showed 99.0% 
reduction in parasitemia following the oral administration of a 30 mg kg-1 dose to P. 
berghei infected mice. However, in terms of physicochemical properties, DL4 
displays very poor aqueous solubility (0.121 mg cm-3 at pH 6.5) and this has been 
addressed in the literature by D. L. Cruickshank et al who reported five novel salts 





Previous co-crystal screening with DL4 
 
The crystal structure of DL4 has been solved and Figure 2 shows two inversion-
related molecules of DL4 that form a hydrogen bonded dimer. The 2-aminopyridine 
moieties in DL4 form a N–H•••N hydrogen bonding motif with graph-set notation 
𝑅2
2(8), indicating an eight-membered  ring with two acceptors and two donors.2  
Figure 1: Chemical structure of DL4. 














In the study by D. L. Cruickshank et al. it was predicted that the 2-aminopyridine 
moiety in DL4 was the group that was most likely to form supramolecular 
heterosynthons with “generally regarded as safe” (GRAS) co-former molecules.2 
Their search of the Cambridge Structural Database revealed 177 hits for the ionic 
supramolecular heterosynthon [Figure 3(a)] between carboxylic acids and                
2-aminopyridine groups and only nine hits for the neutral form [Figure 3(b)]. It had 
also been reported in a separate study that a proton transfer would be expected to 












Dry co-grinding and liquid-assisted grinding (LAG) experiments were performed with 
DL4 and four dicarboxylic acids (fumaric acid, oxalic acid, adipic acid and suberic 
acid) as well as saccharin and salicylic acid.2 Dry co-grinding experiments did not 
reveal any hits, but LAG experiments with DL4 and fumaric acid, salicylic acid and 
Figure 2: Inversion-related molecules of DL4 forming a hydrogen-bonded dimer.  
Figure 3: The ionic (a) and neutral (b) supramolecular heterosynthons that can form between                       
2-aminopyridine moieties and carboxylic acids. 
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saccharin showed evidence for the formation of new phases. Recrystallization of the 
products of the LAG experiments yielded single crystals of the fumarate, salicylate 
and saccharinate salts of DL4. Two additional salts of DL4 (oxalate and suberate 
salts) were prepared by co-precipitation and a novel co-crystal of DL4 and adipic 
acid was prepared using the same method. A semi-quantitative turbidimetric 
solubility assay was used to assess the solubility of the salts in the 20 – 200 μM 
range. The results indicated that the saccharinate and fumarate salts as well as the 




This chapter will discuss the co-crystal screening experiments that were performed 
with DL4. LAG experiments with DL4 revealed three hits that indicated the formation 
of a new phase between DL4 and adipic acid, citric acid and orotic acid. Single 
crystals of the adipate, citrate and orotate salts were obtained by co-precipitation. 
The salts were fully characterised using thermal techniques, IR spectroscopy and   
X-ray structure analysis.   
 
Co-crystal screening  
 
Based on the success of the published co-crystal studies with DL4,2 another series 
of GRAS co-formers containing a carboxylic acid functional group was selected for 
co-crystal screening with DL4. Additionally, co-formers containing an amide 
functional group were investigated.  LAG was used as the first stage of co-crystal 
screening and the results of these experiments informed the choices for the co-
precipitation stage. In general 10 mg of DL4 was ground with an equimolar amount 
of the co-former in the presence of a minimum amount of either methanol or 
acetonitrile. The results of the experiments (Table 1) indicated that a new phase had 
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Table 1: Co-formers, solvents and experimental outcomes for the LAG experiments with DL4.                  
All experiments were performed using a 1:1 molar ratio of DL4 and the co-former.  
Co- former Solvent Product 
L-(-)-malic acid Methanol Physical mixture 
Propionamide Methanol Physical mixture 
Benzamide Methanol Physical mixture 
Orotic acid Methanol New phase 
Uric acid Methanol Physical mixture 
Uracil Methanol Physical mixture 
Nicotinic acid Methanol Physical mixture 
L-ascorbic acid Methanol Physical mixture 
Adipic acid Methanol Physical mixture 
L-(+)-tartaric acid Methanol Amorphous 
Isonicotinamide Methanol Physical mixture 
Citric acid Methanol New phase 
Propionamide Acetonitrile Physical mixture 
Benzamide Acetonitrile Physical mixture 
Uric acid Acetonitrile Physical mixture 
Uracil Acetonitrile Physical mixture 
Nicotinic acid Acetonitrile Physical mixture 
L-ascorbic acid Acetonitrile Physical mixture 
Adipic acid Acetonitrile New phase 
L-(+)-tartaric acid Acetonitrile Amorphous 
Isonicotinamide Acetonitrile Physical mixture 
Citric acid Acetonitrile New phase 
   
Co-precipitation experiments were performed in cases where the results indicated 
the formation of a new phase. Different solvent systems were used for each 
combination of DL4 and co-former, but in general equimolar amounts of DL4 and the 
co-former were dissolved separately in a common solvent. The solutions were 
combined while stirring and then filtered into a clean vial and allowed to crystallize 
under ambient conditions. The results are summarised in Table 2.  
 
Table 2: Co-formers, solvents and experimental outcomes for the co-precipitation experiments with DL4. 
All experiments were performed using a 1:1 molar ratio of DL4 and the co-former. 
Co-former Solvent Product 
Adipic acid Acetonitrile Salt 
Citric acid Methanol Salt 
Citric acid Ethanol No crystal 
Citric acid Acetonitrile No crystal 
Citric acid 1,4-dioxane No crystal 
Citric acid Ethyl acetate No crystal 
Orotic acid Ethanol-water (50:50 v/v) Salt 
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DL4ADI: DL4-adipic acid 2:1 salt  
 
LAG and single crystal preparation    
 
10 mg of DL4 and an equimolar amount of adipic acid were ground for 15 minutes 
with a mortar and pestle while small drops of acetonitrile were added. The product 
was analysed by PXRD and the results indicated that a new phase had formed. The 
PXRD traces for DL4, adipic acid and the product from the LAG experiment are 
shown in Figure 4. New peaks can be seen in the PXRD trace for the product at 2θ 
positions 6.78, 7.78, 9.03, 11.23, 13.62 and 15.11°. However, there are still peaks in 
the PXRD trace of the product that coincide with peaks of DL4, indicating that the 




Figure 4: PXRD traces for adipic acid, DL4 and the product of LAG. 
 
Single crystals of the DL4ADI salt were obtained by co-precipitation. 10 mg of DL4 
and an equimolar amount of adipic acid were dissolved separately in a minimum 
amount of acetonitrile with gentle heating (~40 °C). The solutions were combined 
while stirring and then filtered through a 0.45 μm nylon filter into a clean vial and left 
on the bench to crystallize. Yellow-brown plate-like crystals appeared within 7 days.  





Crystals of DL4ADI were dissolved in DMSO-d6 and analysed using 1H NMR 
spectroscopy. The spectrum and signal integrations are shown in Figure 5 and  
Table 3 respectively. The results suggest a 2:1:2 DL4:adipic acid:acetonitrile 
stoichiometry (the correct stoichiometry was subsequently determined to be 2:1:1:2                           

















Table 3: 1H NMR integration for DL4ADI. 
Proton δ (ppm) Multiplicity J (Hz) Integration Experimental/ 
Theoretical 
C-He 8.44 d 2.45 1.87 0.94 
C-Hg 8.32 d 2.45 1.83 0.92 
C-Hc + C-Hd 7.95 m  7.89 0.99 
C-Hi 7.85-7.88 d of d 6.11, 2.45 1.95 0.98 
C-Hf 7.75 d 2.45 1.97 0.99 
C-Hh 6.94 d 9.29 1.87 0.94 
2 x N-H2 6.04 s (br)  3.72 0.93 
3 x O-CH3 3.92 s  *6.00 1 
C-Hb 2.19-2.23 m  7.96 0.50 
3 x C-H3 (acetonitrile) 2.08 s  5.37 0.90 
C-Ha 1.50-1.53 m  7.90 0.49 
*reference integral 
Figure 5: 1H NMR spectrum of DL4ADI in DMSO-d6. 
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Infrared (IR) Spectroscopy  
 
The IR spectra for DL4ADI and the desolvated form of the salt are shown in Figure 6. 
The IR spectrum for DL4ADI shows peaks in the range of 1400 –1600 cm-1 that 
correspond to the carboxylate stretching frequency. This suggests that an acid-base 
reaction had taken place, resulting in the formation of an adipate ion. The peaks 
associated with the carboxylate stretching frequency are also observed in the 
spectrum for the desolvated form of DL4ADI, indicating that the “salt-like” nature of 
the crystal structure was maintained after the solvent had been removed by 
controlled heating. This demonstrates that it is possible to eliminate the acetonitrile, 
which does not occur on the GRAS list, whilst leaving the residual salt intact. 
 
Figure 6: IR spectra for DL4ADI and the desolvated form of DL4ADI. 
 




Representative photographs taken during a HSM experiment are shown in Figure 7. 
The crystals of DL4ADI were heated at a rate of 10 K min-1. The photograph taken at 
104 °C shows the first bubbles starting to appear, indicating the onset of desolvation. 
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The bubbling becomes more pronounced as the desolvation continues until 112 °C. 


















TGA and DSC 
 
The TGA experiment with DL4ADI was performed in triplicate and a representative 
trace is shown in Figure 8.  There is a mass loss of 7.4 ± 0.2% between 93 °C and 
150 °C corresponding to the loss of two acetonitrile molecules [calculated 7.6%  for a 
(DL4 cation)2:adipate ion:adipic acid:(acetonitrile)2 composition]. The second mass 
loss of 26.6 ± 0.3% that occurs between 150 °C and 250°C indicates the onset of 
decomposition and is most likely due to the loss of two molecules of adipic acid and 
(calculated 26.8%). Based on the 1H NMR, IR and TGA data the chemical formula 
for the salt was determined to be (C18H18N3O3S)+•½(C6H8O4)2-•½(C6H10O4)•(C2H3N).  
 
Figure 7: Representative HSM photographs for DL4ADI. 




Figure 8: Representative TGA trace for DL4ADI. 
 
The DSC trace seen in Figure 9 shows a sharp endotherm between 94 °C and      
103 °C. This endotherm peaks at 97 °C and indicates the fusion of DL4ADI        
(ΔHfus = 88.2 kJ mol-1). The sample starts to decompose after fusion has occurred.  
 
 
Figure 9: Representative DSC trace for DL4ADI. 
 
Crystal structure analysis  
 
Data-collection and space group determination 
 
Crystal intensity data were collected on a Bruker KAPPA APEX II DUO single crystal 
X-ray diffractometer. The data were corrected for absorption effects using the 
program SADABS4 and Lorentz-polarization corrections were applied using the 
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program SAINT.5 The Laue symmetry was found to be 1 indicating the triclinic 
crystal system and the space group P1 was identified from the mean                    
E2 -1 parameter value of 1.244 (obtained using the program XPREP)6 indicating 
centrosymmetry. 
 
Structure solution and refinement 
 
Crystal and refinement data for DL4ADI are shown in Table 4. The structure was 
solved by direct methods using program SHELXS-977 within the XSEED interface.8 
The structure was refined using full-matrix least-squares with SHELXH-97.7 All of the 
ordered non-hydrogen atoms were refined isotropically initially and then 
anisotropically. All of the hydrogen atoms were initially located in difference Fourier 
syntheses and they were subsequently placed in idealised positions using a riding 
model and refined isotropically with Uiso in the range 1.2-1.5 times those of their 
parent atoms. The structure of DL4ADI displayed a high degree of disorder that 
proved to be challenging to model. Both of the acetonitrile molecules were 
disordered and after it became evident that applying a disordered model to these 
molecules would not be feasible, they were refined isotropically. The large residual 
electron density peak of 1.2 e Å-3 is located close to one of the disordered 
acetonitrile molecules. The phenyl rings in both of the DL4 molecules were also 
found to be disordered over two orientations and were refined isotropically. The 
disordered phenyl rings were modelled using part numbers and their site-
occupancies were treated as variables and allowed to refine, the major and minor 
components having s.o.f.s of x and 1-x, x being a least-squares variable. The 
geometry of the disordered phenyl rings was very poor and an attempt to improve it 
involved imposing FLAT constraints. However, it was not possible to obtain a planar 
geometry for the phenyl rings. Despite the high degree of disorder, it was 
nevertheless possible to observe the main features of the structure, namely that it 
was a salt and not a co-crystal. The hydrogens on both pyridine nitrogen atoms were 
located in the difference Fourier maps and the CO bond lengths of the adipate ions 
were all in the range 1.228(6) to 1.290(6) Å, indicating that proton transfer had taken 
place. Furthermore, the CO bond lengths for the independent adipic acid moieties 
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were in the range 1.191(6) to 1.212(7) Å for the C=O bonds and 1.309(7) to 1.346(7) 
Å for the C–O bonds. 
  
One possible reason for the high degree of disorder in the structure could be the 
effects of collecting the crystal intensity data at low temperature [173(2)K]. It is 
possible that upon cooling, small differences induced between the original chemical 
units caused the unit cell contents to double. The two halves of the ASU are 
practically identical and are related to each other by a translation of ~½ along the     
a-axis (i.e. ~5.3 Å). This doubling effect was also evident when the reflections were 
viewed using the program Layer9, which showed strong/weak alternation in the 
intensities of the reflections in the reciprocal lattice levels hkl with h = 2n and            
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Table 4: Data-collection and refinement parameters for DL4ADI.    
 
Molecular structure  
 
The asymmetric unit of DL4ADI consists of two molecules of DL4 in protonated form, 
two half adipate ions, two half adipic acid molecules and two molecules of 
acetonitrile (Figure 10).  The two independent cations of DL4 in the asymmetric unit 
possess a proton that has been fully transferred to each of the nitrogen atoms N15A 
and N15B (Figure 11). Each independent adipate ion is located on a centre of 
inversion. The same applies to the adipic acid molecules.  
 
Molecular formula  (C18H18N3O3S)+•½(C6H8O4)2-•½(C6H10O4)•(C2H3N) 
Formula weight (g mol-1)  542.66  
Crystal system  Triclinic 
Space group  P1  
a (Å)  10.529(1) 
b (Å)  14.370(2) 
c (Å)  18.191(2) 
α (°)            88.388(2) 
β (°)  88.026(2) 
γ (°) 81.527(2) 
V (Å)3 2720.0(5) 
Z  4 
Dc (g cm-3)  1.325  
μ (Mo Kα) (mm-1)  0.170  
F(000)  1144 
Data-collection temp. (K) 173(2) 
Crystal size (mm3)  0.08  0.19  0.30   
Range scanned θ (°)  1.1 - 28.4  
Index ranges ±h, ±k, ±l -14, 14 ; -19, 19 ; -24, 24  
Reflections (total) 74180  
Independent reflections  13602 
Reflections with I>2σ(I)  7054 
No. of parameters 638 
Rint 0.058 
S 1.10 
R1 [I>2σ(I)]  0.0976 
Reflections omitted 0 
wR2 0.3062 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] 0.0949, 9.7998 
(Δ/σ)mean  <0.001 
Δρmin,max (e Å-3)  -1.40 and 1.21 




Figure 10: Asymmetric unit (ASU) of DL4ADI showing thermal ellipsoids at the 50% probability level. 
Hydrogen atoms have been omitted for clarity. The adipate ions and adipic acid molecules are located on 
centres of inversion and therefore only half of each of these moieties contributes to the ASU.  
 
 
Figure 11: Left: labelling scheme for the two DL4 cations in DL4ADI. Right: labelling scheme for the 
acetonitrile molecules, adipic acid molecules and adipate ions. Only hydrogens involved in hydrogen 
bonding interactions have been displayed.  
 
Hydrogen bonding and crystal packing 
 
The N15B–H15A•••O35B and N17B–H17C•••O34Ba (a = -1+x, y, z) intermolecular 
hydrogen bonding interactions between the DL4 molecule and the adipate anion 
generate a 𝑅22(8) hydrogen bonded motif (1 in Figure 12). The N17B–H17D•••O24Ab 
(b = 1-x, 1-y, 1-z) and N17A–H17B•••O24Bb interactions generate a 𝑅22(18) 
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hydrogen bonded motif (2 in Figure 12). The adipic acid molecules and adipate 
anions are hydrogen bonded to each other via O30B–H30B•••O35Ba and                 
O34A–H34A•••O29A interactions. The principal hydrogen bonding interactions are 
listed in Table 5.  
 
Figure 12: Packing diagram of DL4ADI viewed along [1 0 0] showing the principal hydrogen bonding 
interactions. Symmetry operators: a = -1+x, y, z; b = 1-x, 1-y, 1-z.  
 
Table 5: Principal hydrogen bonding interactions in DL4ADI. 
Interaction D–H (Å) H•••A (Å) D•••A (Å) D–H•••A (°) 
N15A–H15A•••O29A 0.88 1.75 2.613(6) 167 
N15B–H15B•••O35Ba 0.88 1.73 2.597(5) 168 
N17A–H17A•••O30A 0.88 1.97 2.834(6) 166 
N17A–H17B•••O24Bb 0.88 2.34 3.051(5) 138 
N17B–H17C•••O34Ba 0.88 1.97 2.832(6) 167 
N17B–H17D•••O24Ab 0.88 2.34 3.041(5) 137 
O30B–H30B•••O35B 0.84 1.82 2.636(5) 163 
O34A–H34A•••O29A 0.84 1.80 2.629(6) 167 
a-1+x, y, z; b1-x, 1-y, 1-z   
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Figure 13 shows the packing diagram for DL4ADI viewed along [0 0 1]. 
The hydrogen bonded motifs pack in layers that straddle the (2 3 0) planes.  
 
Figure 13: Packing diagram of DL4ADI viewed along [001]. 
 
Comparative PXRD  
 
The high level of agreement between the experimental and calculated PXRD traces 
for DL4ADI (Figure 14) confirms that the single crystal which was analysed is 
representative of the bulk material. Differences in peak angular positions are due to 
the different temperatures involved (294 K and 173 K for the experimental and 
calculated patterns respectively).  
 
Figure 14: Calculated and experimental PXRD traces for DL4ADI.   
Chapter 5: Co-crystal screening with DL4 
72 
 
Solubility assessment  
 
A semi-quantitative turbidimetric solubility test in phosphate buffer solution (PBS) at 
25 ± 0.5 °C was performed with DL4 and DL4ADI according to the method described 
by Pérez et al.10 Although this method of solubility testing did not provide a discrete 
solubility value, it was useful in that the result could be compared with the apparent 
solubility of the co-crystal between adipic acid and DL4 reported in the literature.2 
Figure  15 is a plot of the average absorbance at 620 nm for three replicates of each 
sample for a concentration range spanning 20 – 200 μM. The approximate solubility 
can be defined as the concentration above which there is a significant positive 
deviation from the baseline. A line that does not deviate from the baseline indicates 
that no precipitation has occurred and therefore that the solubility is greater than 200 
μM.   
 
The results indicate that the apparent solubility of DL4ADI is lower than that of DL4. 
This is in contrast to the results reported for the co-crystal between adipic acid and 
DL4, where the co-crystal displayed an apparent solubility greater than that of DL4. 
 
Figure 15: Plot of absorbance versus concentration for (a) DL4, (b) DL4ADI, (c) respirine and (d) 
hydrocortisone. Resperine and hydrocortisone are standards with known solubilities in PBS.  
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CITDL4: DL4-citric acid 1:1 salt  
 
LAG and single crystal preparation 
 
10 mg of DL4 was co-ground with an equimolar amount of citric acid for 15 minutes 
while small drops of either methanol or acetonitrile were added. The products were 
analysed using PXRD and the traces are shown in Figure 16. The PXRD traces for 
these products are very similar and clearly different from the component traces. This 
is a strong indication that the same new phase had formed during both LAG 
experiments. Single crystals of DL4CIT were obtained from a co-precipitation 
experiment where 10 mg DL4 and an equimolar amount of citric acid were dissolved 
separately in ~1 cm3 of methanol. The solutions were combined while stirring and 
then filtered through a 0.45 μm nylon filter into a clean vial and left to crystallize on 
the bench. Crystals appeared after 2-3 weeks.  
 





Crystals of DL4CIT were dissolved in DMSO-d6 and analysed using 1H NMR 
spectroscopy (Figure 17). The proton signals were integrated (Table 6) and the 
results confirmed the DL4:citric acid stoichiometry to be 1:1. 
 




Figure 17: 1H NMR spectrum of DL4CIT in DMSO-d6. 
 
Table 6: 1H NMR integration for DL4CIT. 
Proton δ (ppm) Multiplicity J (Hz) Integration Experimental/ 
Theoretical 
C-He 8.44-8.43 d 2.45 0.91 0.91 
C-Hg 8.31 d 3.18 0.89 0.89 
C-Hc + C-Hd 7.92-7.97 m  3.84 0.96 
C-Hi 7.85-7.88 d of d 2.69, 5.87 0.90 0.90 
C-Hf 7.76 d 2.45 0.94 0.94 
C-Hh 6.92-6.95 d 9.29 0.87 0.87 
2 x N-H2 6.06 s (br)  1.81 0.91 
O-CH3 3.92 s  *3.00 1.00 
Ha + Hb 2.64-2.78 q 15.41, 24.7 4.51 1.13 
*reference integral 
 
IR Spectroscopy  
 
The IR spectrum of DL4CIT (Figure 18) provided evidence for the formation of a salt 
between citric acid and DL4. The peaks at 1421, 1492 and 1589 cm-1 are 
characteristic of the carboxylate stretching frequency, indicating that a proton has 








Figure 18: IR spectrum of DL4CIT. 




The representative HSM photographs for DL4CIT are shown in Figure 19. Crystals of 
DL4CIT were heated at 10 K min-1. The photograph recorded at 152 °C shows small 
bubbles appearing and this can be attributed to the loss of solvent. The bubbling 
continues until the sample melts at 169 °C. 
 
 
Figure 19: Representative HSM photographs of DL4CIT. 
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TGA and DSC 
 
TGA was used to quantify the water content of DL4CIT. The TGA trace (Figure 20) 
shows an average mass loss of 3.2 ± 0.2% (n = 3) between 50 °C and 70 °C. This is 
consistent with the loss of one water molecule per ASU (calculated 3.2% for a 1:1:1 
DL4:citric acid:water composition). Based on the 1H NMR, IR and TGA data, the 
chemical formula for the salt was determined to be (C18H18N3O3S)+•(C6H8O7)-•(H2O). 
 
Figure 20: TGA trace for DL4CIT. 
 
The DSC trace of DL4CIT (Figure 21) shows a broad endotherm spanning the 
temperature range 40 – 80 °C, which corresponds to dehydration. The endotherm 
between 153 °C and 165°C (peak 160°C) indicates the melting of the salt. ΔHfus was 
estimated to be approximately 34.1 kJmol-1, but this value is compromised by the 













Figure 21: DSC trace for DL4CIT. 
Chapter 5: Co-crystal screening with DL4 
77 
 
Crystal structure analysis 
 
Data-collection and space group determination 
 
Crystal intensity data were collected on a Bruker KAPPA APEX II DUO single crystal 
X-ray diffractometer. Lorentz-polarization corrections were applied using the program 
SAINT5 and the data were corrected for absorption effects using the program 
SADABS.4 The crystal system was found to be triclinic and the E2 -1 value of 0.951 
obtained using the program XPREP6 confirmed the space group as P1.   
 
Structure solution and refinement 
 
The structure of DL4CIT was solved by direct methods using program SHELXS-97,7 
revealing all of the non-hydrogen atoms in DL4 and citric acid.  These atoms were 
placed and following their refinement with isotropic thermal parameters they were 
refined anisotropically using SHELXH-97.7 The difference Fourier maps revealed a 
hydrogen atom on the pyridine nitrogen atom of the DL4 molecule, indicating that a 
salt had been formed. Furthermore, the C–O bond lengths of one of the carboxyl 
groups on the citric acid moiety were found to be 1.260(2) Å and 1.249(2) Å, 
confirming the presence of a carboxylate ion and hence indicating that a proton 
transfer had taken place. All of the hydrogen atoms were located in difference 
Fourier syntheses and were placed in idealised positions using a riding model and 
refined isotropically with Uiso values 1.2 – 1.5 times those of their parent atoms. The 
difference Fourier maps revealed a large electron density peak that was initially 
attributed to the oxygen atom of one water molecule, as confirmed by TGA. 
Following several refinement cycles, however, it became clear that the oxygen atom 
was disordered over several positions and could not be modelled appropriately. 
Therefore, the tentative water oxygen components of the disordered O atom were 
deleted from the model and a new intensity data file (.hkl) was calculated using the 
SQUEEZE tool in the program PLATON.11 SQUEEZE determines the contribution of 
the disordered water molecule to the intensities, which means that the intensity 
values in the new .hkl file would be adjusted to reflect the contribution from the water 
molecule. SQUEEZE also calculates the void accessible volume in the structure and 
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integrates the electron density in the void to give an electron count which can be 
used to quantify the solvent. The solvent accessible void was found to be 94.7 Å3 
and the electron density integrated for 32 electrons per unit cell. Z is 2 and therefore 
the electron count for the asymmetric unit would be 16, which corresponds to about 
1.5 water molecules. Although there is a discrepancy between the number of water 
molecules determined using TGA and the number estimated from the electron count 
(1 and 1.5 respectively), more weight was accorded to the consistent estimate of 
water content using the TGA technique. After using the SQUEEZE tool, the structure 
was refined against the set of modified intensity data.  The data-collection and 
refinement parameters for DL4CIT are shown in Table 7. 
 
Table 7: Data-collection and refinement parameters for DL4CIT. 
Molecular formula  (C18H18N3O3S)+•(C6H7O7)- 
Formula weight (g mol-1)  547.54 
Crystal system  Triclinic  
Space group  P1 
a (Å)  5.0688(4) 
b (Å)  13.576(1) 
c (Å)  18.955(2) 
α (°)            82.164(2) 
β (°)  85.900(2) 
γ (°) 83.068(2) 
V (Å)3 1283.5(2) 
Z  2 
Dc (g cm-3)  1.417 
μ (Mo Kα) (mm-1)  0.188 
F(000)  572 
Data collection temp. (K) 173(2) 
Crystal size (mm3)  0.05 × 0.14 × 0.45 
Range scanned θ (°)  3.0 – 27.9 
Index ranges ±h, ±k, ±l -6, 6; -17, 17; -24, 24  
Reflections (total) 21963 
Independent reflections  6115 
Reflections with I>2σ(I)  4968 
No. of parameters 350 
Rint 0.029 
S 1.05 
R1 [I>2σ(I)]  0.0391 
Reflections omitted 10 
wR2 0.1051 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] 0.0571, 0.2609 
(Δ/σ)mean  <0.01 
Δρmin,max (e Å-3)  -0.32, 0.41 
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Molecular structure  
 
The asymmetric unit (ASU) and labelling scheme of DL4CIT are shown in Figure 22. 
The ASU consists of one molecule of DL4 that has been protonated at N15 and one 
citrate ion that has been deprotonated.  
 
Figure 22: Asymmetric unit of DL4CIT showing thermal ellipsoids at the 50% probability level. 
 
Crystal packing and hydrogen bonding  
 
The principal hydrogen bonding interactions in DL4CIT are shown in Figure 23 and 
the corresponding bond lengths and angles are listed in Table 8. The                               
N15–H15•••O35 and N17–H17A•••O36 interactions between the DL4 cation and the 
citrate anion generate a 𝑅2 2 (8) hydrogen bonding motif (1). The three interactions                         
N17–H17A•••O36, N17–H17B–O37a (a = 2-x, 2-y, 1-z) and O38a–H38•••O36 
between the DL4 cation and the citrate anion form a hydrogen bonding motif (2) with 
graph-set notation 𝑅3 2 (8). The citrate anions interact via the O31–H31•••O32
a 
hydrogen bond and the centre of inversion at 0, ½, ½ generates a hydrogen bonded 
Chapter 5: Co-crystal screening with DL4 
80 
 
dimer (3) with graph-set notation 𝑅2 2 (8). There is also an O33–H33•••O36 
intramolecular hydrogen bonding interaction in the citrate anion.  
 
 
Figure 23: Hydrogen bonding interactions in DL4CIT (Only the H atoms relevant in principal H-bonding 
have been included). Symmetry operator: a = 2-x, 2-y, 1-z.  
 
Table 8: Principal hydrogen bonding interactions in DL4CIT. 
Interaction D–H (Å) H•••A (Å) D•••A (Å) D–H•••A (°) 
N15–H15•••O35 0.88 1.74 2.614(2) 172 
N17–H17A•••O36 0.88 2.00 2.806(2) 152 
N17–H17B•••O37a 0.88 2.35 2.860(2) 117 
O31–H31•••O32a 0.95 1.67 2.608(2) 167 
O38a–H38•••O36 0.90 1.81 2.708(1) 174 
O33–H33•••O35b 0.83 2.06 2.823(1) 152 
O33–H33•••O36 0.83 2.27 2.708(1) 113 
a 2-x,1-y,1-z; b 1+x, y, z  
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When viewed down [0 1 0] the asymmetric units in DL4CIT display a zig-zag packing 
arrangement (Figure 24).  
 
 
Figure 24: Packing diagram of DL4CIT viewed along [0 1 0]. 
 
Comparative PXRD  
 
The experimental and calculated PXRD traces for DL4CIT are shown in Figure 25. 
The traces are practically identical, confirming that the single crystal that was 
analysed is representative of the bulk material.  
 
Figure 25: Calculated and experimental PXRD traces for DL4CIT. 
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Solubility assessment       
 
DL4CIT could be prepared by LAG, which proved to be a quick and easy method of 
scaling up the material for solubility analysis. Values for the equilibrium solubility of 
DL4 and DL4CIT were obtained using the methodology described in Chapter 2. 
Excess amount of material was added to 5 cm3 of a 1% ethanol-water (v/v) solution 
with stirring at constant temperature (25 ± 0.5 °C). After 72 hours the solutions were 
filtered and the concentration of DL4 was determined using UV-visible spectroscopy. 
The values for the apparent solubility of DL4 and DL4CIT were found to be         
0.033 mM and 1.61 mM respectively and were based on triplicate measurements. 
The results demonstrate that the citrate salt form of DL4 had an apparent solubility 
that was 48 times greater than that of untreated DL4.  
 
DL4ORO: DL4-orotic acid 1:1 salt   
 
LAG and single crystal preparation 
 
The LAG experiment between DL4 and orotic acid resulted in a product with a PXRD 
trace as shown in Figure 26. There are prominent new peaks that emerge in the 
trace of the product between 2θ-positions 7.6° and 15.2°. This gave strong evidence 
that a new phase had resulted from the LAG experiment. Single crystals were 
prepared by co-precipitation using a 50% ethanol-water (v/v) mixture. A mixed 
solvent system was required, because orotic acid is insoluble in common organic 
acids, but sparingly soluble in water at 25 °C while DL4 is soluble in ethanol, but 
insoluble in water. The components were each dissolved separately in 1 cm3 of 50% 
ethanol-water (v/v) at elevated temperature (~50 °C). The solutions were combined 
while stirring and filtered through a 0.45 μm nylon filter into a clean vial. The vial was 
left uncapped on the benchtop and needle-like crystals with a slightly yellow colour 
appeared after 4-6 days. The vial was sealed after the crystals appeared. 
 









Crystals of DL4ORO were dissolved in DMSO-d6 and analysed using 1H NMR 
spectroscopy. The partial spectrum and integration of the proton signals are shown 
in Figure 27 and Table 9.  Hh in DL4 was used as a reference integral and set to 
1.00. The proton signal for Ha in orotic acid integrated for 1.06, indicating a 1:1 DL4: 
orotic acid stoichiometry.  
 
Figure 27: Partial 1H NMR spectrum of DL4ORO.  
Chapter 5: Co-crystal screening with DL4 
84 
 
Table 9: 1H NMR integration for DL4ORO. 
Proton δ (ppm) Multiplicity J (Hz) Integration Experimental/ 
Theoretical 
C-He 8.44-8.43 d 2.45 0.97 0.97 
C-Hg 8.31 d 2.45 0.99 0.99 
C-Hc + C-Hd 7.92-7.97 m  4.68 1.2 
C-Hi 7.85-7.88 d of d 2.45, 6.11 1.13 1.1 
C-Hf 7.78 d 2.45 1.13 1.1 
C-Hh 6.92-6.95 d 8.56 *1.00 1.00 
2 x N-H2 6.11 s (br)  1.87 0.94 
C-Ha 5.98 d 1.96 1.06 1.1 
*reference integral. 
 
IR spectroscopy   
 
There are sharp peaks in the IR spectrum of DL4ORO (Figure 28) associated with 
the carboxylate stretching (1409, 1486 and 1596 cm-1). This indicates that an acid-
base reaction occurred between DL4 and orotic acid and that the product is therefore 
a salt and not a co-crystal. 
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Representative HSM photographs for DL4ORO are shown in Figure 29. The crystals 
start to change colour at 160 °C and melting occurs concurrently with decomposition 
as can be seen in the photographs taken at 244 °C and 250 °C.  
 
 
Figure 29: Representative HSM photographs of DL4ORO. 
 
TGA and DSC 
 
The TGA trace for DL4ORO (Figure 30) shows a mass loss of 0.4 ± 0.1% (n = 2) 
between 30 °C and 50 °C. This is consistent with the loss of 0.11 – 0.12 water 
molecules (calculated 0.4% for a 1:1:0.11 DL4:orotic acid:water composition). The 
onset of decomposition occurs at 231 °C and this is consistent with the thermal 
events observed during the HSM experiment. The second mass loss of 30.7% 
between 260 °C and 286 °C is attributed to the loss of the orotic acid molecule 
(calculated 30.4%).  




Figure 30: TGA trace for DL4ORO. 
 
The DSC trace for DL4ORO (Figure 31) shows an endotherm spanning the 
temperature range 235 – 249 °C (peak 243 °C) corresponding to the melting of the 
salt (ΔHfus = 55.0 kJ mol-1). There is an exotherm that occurs immediately after 
fusion and this is attributed to the decomposition of DL4ORO. The estimated value of 
ΔHfus is compromised by the shift in the baseline caused by this exotherm.  
 
 
Figure 31: DSC trace for DL4ORO. 
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Crystal structure analysis  
 
Data-collection and space group determination 
 
Crystal intensity data were collected on a Bruker KAPPA APEX II DUO single crystal 
X-ray diffractometer. Lorentz-polarization corrections were applied using the program 
SAINT5 and the data were corrected for absorption effects using the program 
SADABS.4 The Laue symmetry was found to be 2/m indicating the monoclinic crystal 
system and the space group P21/c was identified from the systematic absences. 
 
Structure solution and refinement 
 
The structure of DL4ORO was solved by direct methods using program        
SHELXS-97,7 revealing all of the non-hydrogen atoms in DL4 and orotic acid.  
Following isotropic refinement, these atoms were refined anisotropically using 
SHELXH-97.7 Following location of H atoms in difference Fourier syntheses, they 
were placed in idealised positions using a riding model and were refined isotropically 
with Uiso values 1.2 – 1.5 times those of their parent atoms. The hydrogen on the 
pyridine nitrogen of DL4 was located in the difference Fourier map, indicating the 
formation of a salt. The CO bond lengths in the co-former were found to be 1.241(2) 
and 1.252(2) Å, also consistent with a proton transfer between DL4 and orotic acid. 
Data-collection and refinement parameters for DL4ORO are listed in Table 10. The 
difference Fourier maps revealed a low electron density peak that was assumed to 
be a partially occupied oxygen atom, which was located within hydrogen bonding 
distance of the orotate ion. As indicated above, TGA had shown a mass loss of 0.4 ± 
0.1% (n = 2), confirming the presence of 0.11 water molecules. The oxygen atom 
was thus assigned a site-occupancy factor of 0.11 and refined isotropically (final 
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Table 10: Data-collection and refinement parameters for DL4ORO. 
 
Molecular structure  
 
The asymmetric unit and labelling scheme for DL4ORO are shown Figure 32. The 
ASU consists of one molecule of DL4 that has been protonated at N15 and one 
orotate anion. There is also a partial oxygen atom (O1W) attributed to the 0.11 
molecules of water. Due to the low occupancy of the water oxygen atom, no attempt 




Molecular formula  (C18H18N3O3S)+•(C5H3N2O4)+•(H2O)0.11 
Formula weight (g mol-1)  513.49 
Crystal system  Monoclinic 
Space group  P21/c 
a (Å)  4.7043(4) 
b (Å)  12.237(1) 
c (Å)  39.836(3) 
α (°)            90 
β (°)  92.999(2) 
γ (°) 90 
V (Å)3 2290.1(3) 
Z  4 
Dc (g cm-3)  1.489 
μ (Mo Kα) (mm-1)  0.199 
F(000)  1068 
Data collection temp. (K) 173(2) 
Crystal size (mm3)  0.10 × 0.10 × 0.36 
Range scanned θ (°)  1.7 – 27.6 
Index ranges ±h, ±k, ±l -6, 5; -15, 15; -51, 51 
Reflections (total) 34880 
Independent reflections  5294 
Reflections with I>2σ(I)  4306 
No. of parameters 331 
Rint 0.040 
S 1.03 
R1 [I>2σ(I)]  0.0383 
Reflections omitted 2 
wR2 0.0969 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] 0.0435, 0.981 
(Δ/σ)mean  <0.01 
Δρmin,max (e Å-3)  -0.40, 0.30 
















Figure 32: Asymmetric unit of DL4ORO showing thermal ellipsoids at the 50% probability level. 
 
Crystal packing and hydrogen bonding  
 
There is a 𝑅2 2 (8) hydrogen bonding motif (1 in Figure 33) that is generated by the                           
N15–H15•••O32 and N17–H17A•••O33 interactions between the DL4 cation and the 
orotate anion. There is also a 𝑅3 2 (8) hydrogen bonding motif (2) resulting from the 
N17–H17B•••O34a (a = -1-x, ½+y, ½-z), N27–H27•••O35a and N17–H17A•••O33 
interactions. The orotate anions form 𝑅2 2 (9) hydrogen bonded dimers (3) via the 
N27–H27•••O35a and N29–H29•••O33b (b = -1-x, -½+y, ½-z) interactions. The 
principal hydrogen bonding interactions are listed in Table 11. The partially occupied 
water molecule forms a strong hydrogen bonding interaction with the orotate ion, as 
evidenced by the O1W•••O32 distance of 2.89(2) Å. The O1W•••O24c (c = x, -1+y, z) 
and O1W•••O24d (d = 1+x, -1+y, z) distances are 3.06(2) Å and 3.12(2) Å 
respectively, indicating weak hydrogen bonding between the partial water molecule 
and DL4 cations related by the pseudo-translation of ~ a/2.  
 
Table 11: Principal hydrogen bonding interactions in DL4ORO. 
Interaction D–H (Å) H•••A (Å) D•••A (Å) D–H•••A (°) 
N27–H27•••O33  0.88 2.37 2.710(2) 103 
N27–H27•••O35a 0.88 2.12 2.920(2) 151 
N29–H29•••O33b 0.88 1.92 2.801(2) 177 
N15–H15•••O32 0.88 1.79 2.620(2) 156 
N17–H17A•••O33 0.88 1.96 2.839(2) 173 
N17–H17B•••O34a 0.88 2.19 2.780(2) 124 
a -1-x, ½+y, ½-z; b -1-x, - ½+y, ½-z 




 Figure 33: Hydrogen bonding interactions in DL4ORO (Only H atoms involved in hydrogen bonding have 
been included). Symmetry operators: a = -1-x, ½+y, ½-z ; b= -1-x, -½+y, ½-z.  
 
The hydrogen bonding interactions in DL4ORO resemble those seen in DL4CIT. In 
both structures the amino-pyridinium moiety of the DL4 cation forms a 𝑅2 2 (8) 
hydrogen bonding motif (1) with the carboxylate group of the co-former anion. 
Another feature that is common to both salts is the 𝑅3 2 (8) hydrogen bonding motif (2) 
that is generated by the interaction between the amino-pyridinium group and the 
carboxylate groups of two co-former anions. Furthermore, the co-former anions in 
both salts also form hydrogen bonded dimers (synthon 3).  
 
When viewed along [0 1 0] the DL4 cations and orotate anions pack in alternating 
rows that run diagonally along the b-axis (Figure 34).  
 




Figure 34: Packing diagram of DL4ORO viewed along [0 1 0]. Hydrogens have been omitted for clarity. 
 
The crystal packing arrangements that are observed for DL4CIT and DL4ORO are 
very similar: both salts have the DL4 cations and co-former anions packing in 
alternate rows, with the co-formers acting as hydrogen bonded “links” between the 
rows. This observation suggests that small co-former molecules with carboxylic acid 
functional groups could potentially form salts of DL4 that have the same hydrogen 




The high level of agreement between the calculated and experimental PXRD traces 
of DL4ORO (Figure 35) confirms that the single crystal that was analysed is 
representative of the bulk material. Significant differences in several corresponding 
peak intensities are attributed to preferred orientation of the crystallites in the 
experimental sample, which could be due to the acicular morphology of DL4ORO 
crystals observed in HSM. 





Figure 35: Calculated and experimental PXRD traces for DL4ORO. 
 
In summary, only one of the salts of DL4 showed a significant improvement in the 
apparent solubility of DL4. This highlighted the need to explore alternative strategies 
for enhancing the solubility of this compound. The next chapter will present the 
results of CD inclusion experiments conducted with DL4, leading to superior 
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CHAPTER 6: Cyclodextrin inclusion of 3-(6-methoxy- 
pyridin-3-yl)-5-(4-methylsulfonylphenyl)-pyridin-2-amine 
(DL4): a novel antimalarial drug lead 
 
Introduction     
 
As mentioned in the previous chapter, DL4 (Figure 1) has displayed very potent in 
vitro and in vivo antiplasmodial and antimalarial activity respectively, but poor 
aqueous solubility (0.121 mg cm-3 at pH 6.5).1 Five novel salts and a co-crystal of 
DL4 were reported in the literature and it has been shown that the aqueous solubility 
of DL4 could be improved using this strategy.2 However, to date no cyclodextrin (CD) 
inclusion complexes of DL4 have been reported. The use of CDs as a means of 
solubilizing poorly soluble compounds has been reported extensively in the 
literature3 and this chapter will discuss the CD inclusion experiments that were 
carried out with DL4 in an attempt to improve its physicochemical properties.  
 
 
Figure 1: Structure of DL4. 
 
CD inclusion experiments with DL4 
 
Kneading experiments were performed with DL4 and each of the native CDs (α-CD, 
β-CD and γ-CD) to identify any possible CD inclusion complexes. DL4 was kneaded 
with each CD in a 1:1 molar ratio for 20 minutes using a mortar and pestle. Small 
amounts of water were added to allow the kneaded material to maintain a paste-like 
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consistency. The samples were analysed using PXRD and the traces were 
compared with a series of patterns for isostructural complexes of the CDs.4  
 
Kneading experiments with DL4 and α-CD or β-CD did not produce any inclusion 
complexes. However, the PXRD trace from the kneading experiment with DL4 and  
γ-CD indicated that a mixture of an inclusion complex and DL4 had formed. The 
PXRD trace (Figure 2) for the product showed peaks at 2θ positions 7.5, 10.5, 14.2, 
14.9, 15.8, and 16.6° that coincided with peaks from the trace for isostructural γ-CD 
inclusion complexes.4 The PXRD trace of the product also shows peaks from the 
PXRD trace for DL4, which indicates that a mixture of an inclusion complex and DL4 
had formed. The product was recrystallized, but pure crystals of the inclusion 
complex were not obtained. Co-precipitation experiments with the native CDs and 
DL4 did not produce any inclusion complexes.  
 
Figure 2: PXRD traces for DL4, isostructural complexes of γ-CD and the product of kneading DL4 and γ-
CD. 
 
Co-precipitation experiments were performed using three derivatised CDs, namely 
heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB), heptakis(2,3,6-tri-O-methyl)-β-
cyclodextrin (TRIMEB) and hexakis(2,3,6-tri-O-methyl)-α-cyclodextrin (TRIMEA). The 
unit cell of the crystal obtained from co-precipitation with TRIMEA and DL4 was 
checked and it matched the unit cell of pure TRIMEA. Co-precipitation with TRIMEB 
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and DL4 did not produce any crystals. An inclusion complex of DIMEB and DL4 was 
prepared and is henceforth denoted DMBDL4. 
 




DMBDL4 was prepared by adding 5 mg (0.014 mmol) of DL4 to a saturated aqueous 
solution containing an equimolar amount of DIMEB. The solution was stirred for 24 
hours while the temperature was cycled between 25 and 40 °C. The solution was 
filtered through a 0.45 μm filter into a clean vial and placed in the oven at 60 °C. 
Crystals appeared after 4 - 7 days. 
 
The inclusion complex could not be prepared in highly crystalline form by kneading. 
PXRD analysis showed that kneading produced a mixture of DL4 and an amorphous 
phase. All samples of DMBDL4 intended for final use were prepared using a 
modified version of the co-precipitation method described above. The DIMEB was 
dissolved in 1 cm3 of Milli-Q5 water at room temperature and DL4 was dissolved 
separately in 1 cm3 of ethanol at 40 - 50 °C. The two components were combined 
while stirring at room temperature and then filtered through a 0.45 μm nylon filter into 
a clean vial. The open vial was placed in an oven at 60 °C for two hours to allow 
some of the ethanol to evaporate and after two hours the vial was capped and 
sealed. Crystals appeared after 4 - 7 days. 
 
Confirmation of stoichiometry 
 
The host-guest stoichiometry for the DMBDL4 complex was confirmed using 1H NMR 
spectroscopy (Figure 3). The proton signals from DL4 and DIMEB were integrated 
(Table 1) and the results confirm that the host-guest ratio is 1:1. 
 




Figure 3: Partial 1H NMR spectrum of DMBDL4 confirming 1:1 host-guest stoichiometry. 
 
Table 1: 1H NMR integration for the DMBDL4 inclusion complex 
Proton δ (ppm) Multiplicity J (Hz) Integration Experimental/ 
Theoretical 
C-HC 8.44 d 2.57 0.93 0.93 
C-HE 8.32 d 3.12 0.89 0.89 
C-HA + C-HB 7.95 d 2.75 3.88 0.97 
C-HF 7.85-7.88 d of d 8.23, 2.57 0.82 0.82 
C-HD 7.75 d 2.38 0.92 0.92 
C-HG 6.94 d 8.60 0.89 0.89 
2 x N-H2 6.04 s (br)  1.82 0.91 
3 x O-CH3 3.93 s  *3.00 1.00 
3 x O-CH3 3.24 s  3.09 1.03 
C-H1 + C-OH 4.98 m  14.05 1.00 
C-H3 + C-H5 3.70 m  14.45 1.03 
2 x C-H6 3.58 d 3.30 13.83 0.99 
3 x O-CH3 3.52 s  20.94 1.00 
3 x O-CH3 3.27 s  21.85 1.04 













Crystals of DMBDL4 were heated at a rate of 10 K min-1 during a HSM experiment 
and photographs of thermal events were recorded. Small bubbles started to appear 
from 150 °C and the photograph taken at 170 °C (Figure 4) shows two large bubbles 
(highlighted by a red arrow). The crystals melted at 220 °C. The temperatures at 
which thermal events take place during HSM are higher compared to the TGA and 
DSC experiments. This difference is caused by the different sample sizes and 
conditions used during the TGA and DSC experiments.  
 
 
TGA and DSC 
 
TGA was used to quantify the water content of DMBDL4 and the results (Figure 5) 
confirmed the presence of two water molecules per inclusion complex unit in the 
crystal. The TGA traces were recorded in triplicate and an average mass loss of     
2.1  0.1 % was observed between 50 °C and 100 °C corresponding to the loss of 
two water molecules (calculated 2.09 %). TG analysis did not reveal any guest loss 
before the onset of decomposition at 229 °C.  
 
The baseline of the DSC trace (Figure 5) is slightly sloped and this is most probably 
due to an irregularity with the DSC instrument at the time of recording. However, it is 
still possible to observe all of the significant thermal events. There is a broad 
Figure 4: Representative HSM photographs of DMBDL4. 
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endotherm between 50 °C and 130 °C corresponding to the loss of the two water 
molecules. A small exotherm at 179 °C indicates a phase transition which, was 
confirmed using variable temperature PXRD analysis (Figure 14). A sharp 
endotherm at 218 °C indicates the melting point of the complex. 
 
 
Figure 5: Representative TGA (blue) and DSC (red) traces for DMBDL4. 
 
Crystal structure analysis  
 
Data-collection and space group determination 
 
Crystal intensity data were collected on a Bruker KAPPA APEX II DUO single crystal 
X-ray diffractometer. Lorentz-polarization corrections were applied with program 
SAINT6 and absorption corrections were applied using the program SADABS.7 The 
Laue symmetry was found to be 2/m which is consistent with the monoclinic crystal 
system and the space group P21 was identified from the systematic absence of 
reflections 0k0 with k = 2n+1. The chiral space group of the complex is consistent 
with the chiral nature of DIMEB. The crystal system and space group were confirmed 
by the program XPREP.8  
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Structure solution and refinement 
 
Crystal and refinement data for DMBDL4 are shown in Table 2 below. The structure 
was solved by direct methods using program SHELXS-979 within the XSEED 
interface.10 This revealed all of the host and guest atoms as well as the oxygen 
atoms of two water molecules. These atoms were refined using full-matrix least-
squares with SHELXH-97.9 Remarkably, all of the hydrogen atoms, including those 
of the two water molecules, were located in difference Fourier maps. This attests to 
exceptionally high crystal quality and consequently excellent X-ray intensity data, 
which is somewhat unusual for cyclodextrin inclusion complexes. All ordered non-
hydrogen atoms were refined anisotropically. Atom C8 of the glucose unit G3 was 
found to be disordered over two positions and the disordered components C8G3 and 
C832 were included with assigned site occupancy factors x and 1-x (initially set at 
0.6 and 0.4 respectively). The refined final value of x was 0.55. Following their 
location, hydrogen atoms for the host and guest were placed in idealised positions 
using a riding model. The hydrogen atoms of the water molecules were restrained 
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Description of the structure  
 
The asymmetric unit of the DMBDL4 structure (Figure 6) consists of a single DIMEB 
molecule, one DL4 molecule and two water molecules. The DL4 molecule is 
positioned within the DIMEB cavity with the hydrophobic 4-(methylsulfonyl)phenyl 
ring extending into the cavity as far as the primary rim and the more polar                           
2-methoxypyridinyl “tail” protruding from the secondary rim into interstitial spaces in 
the crystal structure. 
Abbreviated Formula DMB•DL4•2H2O 
Complex Formula  C56H98O35•C18H17N3O3S•2H2O  
Formula weight (g mol-1)  1722.78  
Crystal system  Monoclinic  
Space group  P21  
a (Å)  11.3127(6)  
b (Å)  14.5968(7)  
c (Å)  26.187(1)  
α (°)            90.0 
β (°)  96.579(1)  
γ (°) 90.0 
V (Å)3 4295.8(4)  
Z  2  
Dc (g cm-3)  1.332  
μ (Mo Kα) (mm-1)  0.131  
F(000)  1840  
Data collection temp. (K) 173(2) 
Crystal size (mm3)  0.10  0.23  0.30   
Range scanned θ (°)  1.6 - 28.3  
Index ranges ±h, ±k, ±l -15, 15 ; -19, 19 ; -34, 34  
Reflections (total) 48106  
Independent reflections  21356  
Reflections with I>2σ(I)  17693  
No. of parameters 1090 
Rint 0.025 
S 1.02 
R1 [I>2σ(I)]  0.0388 
Reflections omitted 2 
wR2 0.0911 
a, b in w = 1/[σ2(Fo2)+(aP)2+(bP)] 0.0460, 0.4027 
(Δ/σ)mean  <0.001 
Δρmin,max (e Å-3)  -0.38 and 0.28 




Figure 6: Asymmetric unit of DMBDL4 with host shown in blue and the guest in green (left) and space-
filling view of DMBDL4 with the guest shown in green (right). Water molecules have been omitted in the 
space-filling diagram.  
 
Host conformation  
 
The geometric parameters of the O4-heptagon of the host molecule in DMBDL4 are 
listed in Table 3. The 𝑙 parameter measures the distance of each O4 atom to the 
centroid of the heptagon and in a regular heptagon the values would all be equal. 
The values are not all the same for the host molecule, indicating that complexation 
has led to some distortion. The deviations (α) of the O4 atoms from the O4 mean 
plane are very small, indicating a fairly high degree of planarity of the O4-heptagon. 
The D3 parameter, which is not directly defined by the O4-heptagon, measures the 
O•••O distances of the O2n-H•••O(3n-1) hydrogen bonds that link the contiguous 
glucose rings. D3 values for DMBDL4 range from 2.793(2) to 3.004(2) Å, which is 
consistent with these hydrogen bonding interactions. The values for 2 (tilt angles) 
show that the primary sides of G3 and G6 are tilted to a greater extent towards the 
centre of the cavity of the DIMEB molecule than the other glucose units in the 
macrocycle.  




Figure 7: Macrocyclic structure of DIMEB in the inclusion complex (hydrogens have been omitted for 
clarity). The glucoside units are labelled G1-G7 and the atom numbering scheme for a representative 
glucose ring is indicated. 
 
Table 3: Geometric parameters of the host molecule in DMBDL4. 
Residue 𝒍 (Å) D (Å) ϕ (°) d (°) αa (Å) D3b (Å) 2 (°)c 
G1 4.936 4.236 130.7 -1.6 0.0728 2.793 2.93 
G2 5.415 4.288 119.5 -10.9 -0.1875 2.912 15.77 
G3 4.921 4.481 131.2 10.4 -0.0487 3.004 25.28 
G4 4.688 4.455 134.7 4.1 0.2511 2.817 10.91 
G5 5.263 4.199 123.5 -14.5 -0.0858 2.792 4.67 
G6 5.269 4.382 123.0 7.0 -0.2199 2.948 22.15 
G7 4.664 4.550 135.6 4.7 0.2180 2.843 15.00 




The bond lengths and angles of the guest molecule are consistent with those for the 
uncomplexed molecule.2 However, the angles between the aromatic rings of the 
guest molecule do change upon complexation. The angle between the                               
2-methoxypyridine ring and the 2-aminopyridine ring changes from 53.03(8)° to 
61.23(9)° in the complex. Similarly, the angle between the 2-aminopyridine ring and 
the 4-(methylsulfonyl)phenyl ring changes from 27.46(8)° to 34.1(1)° when the 
complex is formed. The orientation of the methylsulfonyl group also changes 
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significantly when the molecule is included in DIMEB (Figure 8). These changes 
indicate that the guest is distorted upon complexation due to interactions with the 
DIMEB molecule in its attempt to be accommodated optimally.  
 
Figure 8: Overlay of the uncomplexed (green) and complexed (red) DL4 molecues. 
 
Two structures for uncomplexed DIMEB (a hydrated molecule of DIMEB) were 
accessed from the CSD,11 namely BOYFOK0412 and CEQCUW.13 Program 
Mercury14 was used to calculate the values for 𝜏2 (Table 4). BOYFOK04 was 
considered to be a representative structure for the uncomplexed DIMEB molecule, 
because the 2 values for this structure are closer to those for DMBDL4 than are the 
values for CEQCUW. Although most of the values for 2 in DMBDL4 and BOYFOK04 
appear to be very similar, there is a significant difference for each of G2, G5 and G6. 
These differences can be explained by viewing the orientation of the guest inside the 
host molecule (Figure 9). The 4-(methylsulfonyl)phenyl ring of DL4 extends towards 
the primary rim of the host and it is orientated in the direction of the G2, G5 and G6 
glucose units, causing these glucoside units to distort. The inclusion of the                        
4-(methylsufonyl)phenyl ring into the DIMEB cavity causes the host molecule to take 
on an elliptical shape. This distortion is also reflected in the values of parameter 𝑙 




Chapter 6: CD inclusion with DL4 
105 
 
Table 4: 𝝉2 values for DMBDL4, BOYFOK04 and CEQCUW. 
Glucosides unit DMBDL4a BOYFOK04 CEQCUW 
G1 2.93 2.8 3.6 
G2 15.77 18.0 16.4 
G3 25.28 27.6 24.3 
G4 10.91 11.0 10.3 
G5 4.67 11.0 6.9 
G6 22.15 14.1 16.6 
G7 15.00 18.6 19.6 
a mean e.s.d 0.01 Å 
 
 
Figure 9:  View from the secondary rim of DMBDL4. The left image shows the 4-(methylsulfonyl)phenyl 
ring extended towards G2, G5 and G6. The image on the right shows a space-filling view from the 
secondary rim.   
 
The differences in the tilt angles for DMBDL4 and BOYFOK04 as well as the 
conformational changes in the guest molecule thus indicate that on complexation 
there are simultaneous conformational changes of DIMEB and DL4 to optimise 




There are seven O2n–HO(3n-1) intramolecular hydrogen bonds which cause the 
DIMEB molecule to adopt a ‘round’ shape (Figure 10).  














Figure 10: Intramolecular hydrogen bonding interactions in the host molecule of DMBDL4.  
 
Figure 11 has been drawn in stereoview to illustrate that the guest forms hydrogen 




Figure 11: Stereoview of the primary hydrogen bonding interactions in DMBDL4. The complex molecule 
in the foreground shows hydrogen bonding interactions emanating from the amine group to the water 
molecules and to another guest molecule (the host molecule of this guest has been omitted for clarity). 
The diagram also shows the water molecules creating hydrogen bonding “bridges” between the complex 
molecules.   
 
Table 5 lists the principal hydrogen bonding interactions that occur within DMBDL4 
with their respective distances and angles. 
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Table 5: Hydrogen bonding interactions in the DMBDL4 inclusion complex. 
Interaction  D-H (Å) H•••A (Å) D•••A (Å) D-H•••A (°) 
Intramolecular 
O3G1−H31B•••O2G2  0.84 2.11 2.912(2) 161 
O3G2−H32B•••O2G3  0.84 2.20 3.004(2) 160 
O3G3−H33B•••O2G4  0.84 1.98 2.817(2) 174 
O3G4−H34B•••O2G5  0.84 1.96 2.792(2) 169 
O3G5−H35B•••O2G6  0.84 2.12 2.948(2) 168 
O3G6−H36B•••O2G7  0.84 2.01 2.843(2) 172 
O3G7−H37B•••O2G1  0.84 1.96 2.793(2) 171 
Intermolecular  
O26−H26A•••N15  0.90 2.06 2.914(2) 159 
O27−H27A•••O6G2 0.89 2.07 2.953(2) 167 
N17−H17B•••O27a  0.88 2.23 3.007(3) 147 
O26−H26B•••O3G3b  0.84 2.13 2.972(2) 172 
O27−H27B•••O26c 0.96 1.88 2.831(2) 172 
N17−H17A•••O24d 0.84  2.13 2.972(2) 172 




The DMBDL4 structure has a cage-type packing arrangement, as seen in Figure 12. 
The 2-methoxypyridinyl “tail” of the guest and the two water molecules are located in 




Figure 12: Packing diagram for DMBDL4 viewed along [0 1 0]. The host molecules are shown in blue and 
the guest in green (hydrogens have been omitted for clarity).   
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Comparative PXRD  
 
The high level of agreement between the experimental and calculated PXRD traces 
for DMBDL4 (Figure 13) confirms that the single crystal which was analysed is 
representative of the bulk material. When more material for further analysis of 
DMBDL4 was required, the inclusion complex was grown by co-precipitation and the 
PXRD traces of the samples were recorded and compared with the calculated trace 
to confirm their purity.  
  
 
Figure 13: Calculated and experimental PXRD traces for DMBDL4. 
 
Variable temperature PXRD  
 
Variable temperature PXRD analysis was used to investigate the phase transition 
that was indicated by the exothermic peak between 165 °C and 187 °C in the DSC 
trace of DMBDL4. The PXRD pattern for a sample of DMBDL4 was recorded at      
30 °C, 165 °C, 175 °C and 185 °C. A comparison of the PXRD traces (Figure 14) 
shows that the PXRD trace at 30 °C is practically identical to the calculated trace. 
However, the PXRD traces recorded at 165 °C, 175 °C and 185 °C are identical and 
clearly different from the trace recorded at 30 °C. This indicates that a phase 
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transition takes place at ~165 °C, resulting in a different PXRD trace. This is 
consistent with the exothermic peak that was observed between 165 °C and 187 °C 
in the DSC trace.  
 
Figure 14: Variable temperature PXRD traces for DMBDL4. 
 
Phase solubility studies  
 
Phase solubility studies were carried out with DL4 and seven different CDs, namely 
α-, β- and γ-CD, partially methylated β-CD (DIMEB), randomly methylated β-CD 
(RAMEB), hydroxypropyl β-CD (HPβCD) and sulfobutyl β-CD sodium salt (SBβCD). 
The phase solubility studies with α-CD, γ-CD, RAMEB and SBβCD produced erratic 
results that were not reproducible and these are therefore not reported. A possible 
reason for the unreliable results with α-CD and γ-CD could be aggregation of these 
host molecules in solution, which would have resulted in significant scattering of UV-
visible radiation. 
 
The phase solubility experiments were performed according to the method described 
by Higuchi and Connors.15 Serial dilutions of each CD solution were prepared and an 
excess amount of DL4 was added to a polytop vial containing 5 cm3 of the CD 
solution. The vials were stirred (500 rpm) at constant temperature (25 ± 0.5 °C) for 
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72 hours. The solutions were filtered through a 0.45 μm nylon filter and diluted 
appropriately before their UV-visible spectra were recorded. The concentration of 
DL4 was determined from a calibration curve (Figure 15) obtained as described in 
Chapter 2.  
 
 
Figure 15: Calibration curve for DL4.   
 
As described in Chapter 4, there are two types of phase solubility profile, namely          
A- and B-type. The former is characterized by an increase in substrate solubility with 
increasing CD concentration while the latter indicates the formation of insoluble 
complexes in solution. The subtypes AL, AP, AN, BS and BL were also defined 
previously. 
 
Figure 16 shows the phase solubility results for DL4 with β-CD. This phase solubility 
profiles has AN-type behaviour, with the solubility of DL4 increasing to a plateau. The 
negative deviation in the solubility of DL4 at the higher concentrations of β-CD could 
be caused by aggregation of β-CD molecules in solution or changes in the solubility 
of the complex in solution. Aggregation of β-CD molecules in solution would cause 
scattering of UV-visible light, resulting in a decrease in the absorbance that is 
detected. The apparent solubility of DL4 (12.08 mg cm-3, equivalent to 0.034 mM at 
25 °C) increased by a factor of 30 at the highest concentration of β-CD investigated.  




Figure 16: Solubility of DL4 as a function of [β-CD] at 25°C.  
 
The phase solubility profiles for the experiments involving DIMEB and HPβCD both 
displayed AL-type behaviour (Figure 17 and Figure 18). The solubility of DL4 
increased with increasing concentration of the CD. At the highest concentration of 
HPβCD used, the apparent solubility of DL4 increased by a factor of more than 80. 
More significantly, the solubility enhancement for DL4 at the highest concentration of 




Figure 17: Solubility of DL4 as a function of [DIMEB] at 25°C.  
  




Figure 18: Solubility of DL4 as a function of [HPβCD] at 25 °C.  
 
Using equation (1), it was possible to calculate the association constants for complex 
formation by using the slopes of the phase solubility profiles. Equation (1), where 𝑆0 
is the intrinsic solubility of DL4 at 25 °C, only applies to 1:1 host-guest complexes 
with the slope of the plot being less than 1. The initial slope was used to calculate 𝐾C 
for the host β-CD (up to 12 mM). The estimated values for 𝐾C are shown in Table 6. 
 
 𝐾C = 
𝑠𝑙𝑜𝑝𝑒
𝑆0(1−𝑠𝑙𝑜𝑝𝑒)
               (1) 
 
Table 6: The apparent stability constants for complexation between DL4 and three CDs. 





The values obtained for the association constants indicate moderately strong binding 
between DL4 and β-CD and strong binding between DL4 and HPβCD. The value of 
𝐾C obtained for the association between DIMEB and DL4 indicates the formation of a 
very stable complex.  
 
 





Phase solubility studies showed that complexation with DIMEB had an enhancing 
effect on the aqueous solubility of DL4. The DMBDL4 inclusion complex was 
subsequently submitted for in vivo pharmacokinetic (PK) and efficacy testing to 
establish whether the inclusion of DL4 in DIMEB had any effect on the in vivo PK 
properties and the efficacy of DL4. While the biological tests were performed by 
specialists in this area, the author of this dissertation was responsible for preparing 
pure samples of DL4 and its inclusion complex in the required form and particle size 
range, for packing microcapsules with these materials, and for establishing the 
appropriate composition of the suspension vehicle for efficacy testing. She also 
engaged closely with the specialists to discuss the interpretation of the results.  
 
Pharmacokinetic studies  
 
In vivo pharmacokinetic testing was carried out by Dr Natasha Strydom and 
colleagues from the Division of Pharmacology at the University of Cape Town (South 
Africa). Nine 6-week-old C57BL/6 mice were divided into an intravenous and two oral 
dosage groups (n = 3).  
 
For the intravenous group, a single 2.5 mg kg-1 dose (formulation: DMSO, PEG, 
EtOH, PPG [2:6:1:7, v/v]) was injected into the penile dorsal vein. Oral dosing was 
achieved using a Torpac capsule loaded with either DL4 or DMBDL4 with a particle 
size range of 100-150 μm. Pure DL4 and the complex DMBDL4 were collected 
separately between a 150 micron and 100 micron sieve to achieve the desired 
particle size range. A single Torpac capsule containing 5 mg kg-1 active dose of 
either DMBDL4 or DL4 was administered orally to groups A and B respectively. 
Blood samples were collected at 0.5, 1, 3, 5, 8 and 24 hours after administration and 
the whole blood concentration of DL4 was determined using a LC-MS assay.16 
 
Table 7 shows the pharmacokinetic parameters for the three groups of mice and the 
mean plot of the DL4 exposure in the three groups is shown in Figure 19. DL4 was 
detectable for the duration of the experiment in all groups. The capsule dosage form 
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caused higher variance in absorption and subsequent pharmacokinetic parameters 
due to the added variability of capsule and compound dissolution. The rate of 
absorption for the DMBDL4 inclusion complex was slower with a significant lag in 
absorption and a longer Tmax of 5 hours compared to 3.7 hours for DL4. Mean 
bioavailability suggests higher bioavailability was observed for DMBDL4, but the 
variance observed between animals makes this inconclusive. However, the DMBDL4 
complex did show less variance compared to DL4, suggesting its absorbance to be 
more consistent and predictable. The apparent half-life of DL4 increased from 3.82 h 
to 6.12 h when DMBDL4 was administered and at 24 hours much higher levels of 
DL4 were observed for the complex (0.3 µM for DMBDL4 compared to 0.06 µM for 
untreated DL4).  
 
Table 7: Pharmacokinetic parameters for the intravenous and capsule dosage groups.  
Parameter IV (2.5 mg kg-1) DMBDL4 (5 mg kg-1 active) DL4 (5 mg kg-1) 
t1/2 (h)a 4.58 6.12 3.82 
Cmax (µM)b 11.4 3.00 2.47 
tmax (hr)c - 5.00 3.70 
Vd (L kg-1)d 0.74 - - 
Cltot (cm3 min-1 kg-1)d 1.94 - - 
AUC (min µmol L-1)e 3666 2131 1548 
Bioavailability (%) - 29 (23 – 35) 22 (4 – 36) 
Conc. at 24 hr (µM) 0.25 0.30 0.06 
a Half-life of DL4, b Maximum concentration of DL4, c Time taken to reach maximum concentration of 













Figure 19: Mean plot of the exposure of DL4 in C57Bl6 mice at a dose of 2.5 mg kg-1 (intravenous group) 
and 5 mg kg-1 (oral dosage groups).  
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The pharmacokinetic results are consistent with a slow release of the DL4 from the 
inclusion complex, resulting in a longer sustained concentration of DL4 over time as 
seen from the increase in apparent half-life. The lag in absorption suggests that the 
DMBDL4 inclusion complex dissociates after gastric emptying and that it is absorbed 
in the duodenum and jejunum, while the more rapid absorption for DL4 suggests that 
its site of absorption is the stomach. Absorption in the duodenum and jejunum is 
more favourable than absorption in the stomach since the capsule spends only a 
short time in the stomach and there is considerable variance in gastric emptying. A 
pH-dependent change in the dissolution for DMBDL4 and DL4 would explain the 
increased variance and the change in apparent half-life. Kinetic solubility studies 
were performed for DL4 and the results (Table 8) show that DL4 has a maximum 
absorption at pH 2, which is consistent with the site of absorption being the stomach. 
To verify the pH-dependent absorption of the DMBDL4 inclusion complex, kinetic 
solubility studies should be performed in different pH media. The data for DMBDL4 
should further be analysed using non-linear mixed effects modelling to account for 
the lag in absorption and observed variance.  
     
Table 8: Kinetic solubility data for DL4. 
pH Equilibrium solubility 
2 4422 μg cm-3 
10.7 10.7 μg cm-3 
11.7 11.7 μg cm-3 
   
 
In vivo efficacy testing 
 
In vivo efficacy testing was carried out by Dr Sergio Wittlin and colleagues at the 
Swiss Tropical and Public Health Institute (Basel, Switzerland). Mice (n = 3) were 
infected with a GFP-transfected P. berghei ANKA strain of malaria and parasitemia 
was determined using standard flow cytometry techniques. The activity of the drug 
lead or inclusion complex was calculated as the difference between the mean 
percentage parasitemia for the control and treated groups expressed as a 
percentage relative to the control group. Compounds were suspended in a 4% 
Tween80 and 9% ethanol [v/v] suspension vehicle and orally administered once per 
day on four consecutive days (4, 24, 48, and 72 h after infection).17 
Chapter 6: CD inclusion with DL4 
116 
 
The results (Table 9) show that there is no significant difference between the 
antimalarial activity of DL4 and DMBDL4 at the 30 mg kg-1 and 10 mg kg-1 dosages. 
This is because the DL4 already has very high antimalarial activity at these dosages 
(>97% activity reduction in parasitemia) and any increase would be insignificant. 
However, there is a noticeable increase in the antimalarial activity of the DMBDL4 
inclusion complex at the 3 mg kg-1 dosage with a 54.44% reduction in parasitemia. 
This is more than double the antimalarial activity for DL4 at the same dosage 
(20.83% parasitemia reduction). This increase is consistent with the results of the PK 
studies, which suggest that the slow-release action of the DMBDL4 inclusion 
complex results in a longer sustained concentration of DL4 over time.  
 
The results of the in vivo studies showed that the inclusion complex DMBDL4, a new 
solid form of DL4, exhibited improved PK properties and increased antimalarial 
activity at low doses (3 mg kg-1) compared to DL4. 
 




Table 9: in vivo efficacy results for DL4 and DMBDL4. 
Substance Dosage 
(mg kg-1) 
Parasitized RBC over 100a Average % of 
control 




  Mouse 1 Mouse 2 Mouse 3     
DL4 30 0.40 0.40 0.40 0.40 1.28 98.72 8.3 
DL4 10 1.00 0.50 0.60 0.70 2.24 97.76 7.0 
DL4 3 18.40 27.40 28.40 24.73 79.14 20.83 3.0 
DMBDL4 30 0.20 0.20 0.20 0.20 0.64 99.36 9.0 
DMBDL4 10 0.50 0.30 0.50 0.43 1.39 98.61 7.0 
DMBDL4 3 12.90 14.60 15.20 14.23 45.56 54.44 7.0 
Control - 28.70 28.50 20.90 26.03 83.33 16.67 3.0 
   aThis is the number of parasitized red blood cells divided by 100. 
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CHAPTER 7: Conclusion 
 
This chapter presents a summary of the most significant outcomes of the study, with 
comments on the possible implications for the future development of the drug leads 
investigated and suggestions for further work. Single crystal X-ray structures were 
determined for two novel antimalarial drug leads. Three salts and one cyclodextrin 
(CD) inclusion complex of a novel antimalarial drug lead were isolated, fully 




No suitable single crystals of DL1 were isolated, precluding the possibility of full 
structural analysis. No supramolecular derivatives of DL1 were obtained from the co-
crystal screening or CD inclusion experiments and this compound proved to be very 
challenging to work with. The lack of positive results of the experiments with DL1 
demonstrates the ability of early supramolecular intervention to streamline the drug 
discovery and design process by identifying compounds that may not be amenable 




Single crystals of DL2 were prepared by recrystallization from acetone and the X-ray 
crystal structure was determined. A search of the Cambridge Structural Database1 
revealed that functional groups that were most likely to form supramolecular 
heterosynthons with the functional groups in DL2 could be provided by carboxylic 
acid and amide co-formers. Nine compounds from these classes were selected for 
co-crystal screening with DL2.  
 
Equimolar amounts of DL2 and each co-former were ground with a mortar and pestle 
for 15 minutes and the products were analysed using PXRD. The results indicated 
that all of the experiments resulted in physical mixtures only. The next stage of the 
co-crystal screening was liquid-assisted grinding (LAG) which involved grinding 
equimolar amounts of DL2 and co-former for 15 minutes while adding small drops of 
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ethanol or acetonitrile. The products of the LAG experiments were analysed using 
PXRD and the results show that only physical mixtures of DL2 and the co-former 
were obtained.  
 
CD inclusion with DL2 was attempted using the kneading and co-precipitation 
methods. DL2 and an equimolar amount of either α-, β- or γ-CD were co-ground for 
20 minutes while drops of water were added to maintain a paste-like consistency. 
The PXRD traces of the products were compared with known powder patterns for 
common isostructural complexes. The PXRD traces of the products did not match 
any of the isostructural patterns and it was found that all of the kneading experiments 
had resulted in physical mixtures of DL2 and the corresponding CD.   
 
The fact that none of the desired products (co-crystals or inclusion complexes) could 
be isolated indicates that DL2 may not be a favourable candidate for further drug 
development. The poor solubility of this compound may be a result of the strong 
intramolecular and intermolecular hydrogen bonding systems in DL2 that could 




The X-ray crystal structure of DL3 was determined after suitable single crystals were 
prepared by recrystallization of DL3 from acetone. DL3 displayed poor solubility in 
both aqueous and organic media and it was therefore necessary to explore 
alternative methods of enhancing its solubility. Phase solubility studies were 
performed with DL3 and both β-CD and HPβCD using the methodology described by 
Higuchi and Connors.2 The phase solubility profiles for β-CD and HPβCD displayed 
AP- and AL-type behaviour respectively. In both cases the apparent solubility of DL3 
increased by a factor of more than 350 at the highest concentration of CD used. The 
results of the phase solubility studies demonstrate that it is possible to significantly 
enhance the apparent solubility of DL3 through CD inclusion. This is an encouraging 
result indicating that aqueous cyclodextrin solutions could have applications as 
media for alternative modes of delivery as well as further biological testing of this 
poorly soluble drug lead.  





Co-crystal screening was carried out with DL4, a novel antimalarial drug lead that 
has been reported in the literature.3 Based on the success of published co-crystal 
studies with DL4 (five salts and one novel co-crystal were reported),4 another series 
of co-formers was selected for co-crystal screening with this drug lead. Three hits 
were identified from liquid-assisted grinding (LAG) experiments and co-precipitation 
experiments were performed in each case.  
 
Three novel salts of DL4 were prepared, namely DL4ADI, DL4CIT and DL4ORO. 
The salts were fully characterised using spectroscopic and thermal techniques and 
the X-ray crystal structure of each salt was determined. It was observed that for each 
of the salts a 𝑅2 2 (8) hydrogen bonding motif formed between the amino-pyridinium 
group of the DL4 cation and the carboxylate group of the co-former anion. 
Furthermore, the crystal packing and principal hydrogen bonding interactions in 
DL4CIT and DL4ORO were found to be very similar. This suggests that co-formers 
with a similar size and structure to orotic acid and citric acid could potentially form 
salts of DL4 that have the same crystal packing and hydrogen bonding interactions 
occurring in DL4CIT and DL4ORO.    
 
A turbidimetric solubility test showed that DL4ADI had an apparent solubility that was 
less than that of DL4. The equilibrium solubility for DL4CIT at 25 ± 0.5 °C was 
determined to be 48 times greater than that of DL4.  
 
Kneading and co-precipitation experiments were carried out with DL4 in an attempt 
to isolate inclusion complexes with CDs. An inclusion complex between DIMEB and 
DL4 (DMBDL4) was isolated and fully characterized. Phase solubility studies were 
performed with DL4 and β-CD, HPβCD and DIMEB. The results revealed that the 
apparent solubility of DL4 increased by factors of 30, 80 and 100 respectively at the 
highest concentrations of β-CD, HPβCD and DIMEB employed.  
 
DMBDL4 was submitted for biological testing to establish whether inclusion of DL4 in 
DIMEB might have any effect on the in vivo pharmacokinetic (PK) properties and 
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efficacy of DL4. The results of in vivo PK studies with DMBDL4 were consistent with 
a slow-release of DL4 from the inclusion complex, as evidenced by the increased 
half-life and Tmax compared to uncomplexed DL4. The results also suggested that 
DMBDL4 dissociated after gastric emptying and that DL4 was absorbed in the 
duodenum and jujenum and not the stomach, as was the case with untreated DL4. In 
vivo efficacy testing showed that the antimalarial activity of DMBDL4 at the 3 mg kg-1 
dose was more than double that of DL4 at the same dosage (54.4% and 20.8% 
respectively). These results demonstrate that CD inclusion was able to produce a 
new solid form of DL4 that exhibited enhanced aqueous solubility and antimalarial 
activity at low doses compared to DL4.  
 
This study demonstrates that supramolecular modification of poorly soluble 
compounds can result in new solid forms with superior physicochemical properties. It 
also highlights the effectiveness of employing supramolecular intervention in parallel 
with the drug discovery process as a tool for selecting suitable candidates for further 




Phase solubility studies showed that DL3 forms 1:1 complexes with β-CD and 
HPβCD in solution. Solid-state kneading and co-precipitation experiments with 
cyclodextrins should be performed in an attempt to isolate inclusion complexes 
between DL3 and these host compounds. 
 
If the inclusion complex DMBDL4 dissociates after gastric emptying and DL4 is 
absorbed in the duodenum and the jujenum, then the solubility of DMBDL4 would be 
greatest at pH 7.4. Kinetic solubility studies should be carried out with DMBDL4 to 
determine whether there is a pH-dependent change in the absorption of DMBDL4 
and thereby determine its site of absorption.7  
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Crystallographic data files 
 
This document contains all of the PXRD traces from the co-crystal and CD inclusion 
experiments that were not included in the dissertation.  
 
The crystallographic data files and checkcif reports for all of the X-ray crystal 
structures have been included in the folders listed in Table 1. The crystallographic 
files included in each folder have the extensions .res, .hkl, .cif, .fcf, .xl, .sup and .lis. 
A checkcif document for each structure has also been included in .pdf format. All of 
the folders listed in Table 1 are contained in one folder labelled “Appendix”.  
 
Table 1: The names and contents for each of the folders included in the Appendix folder. 
Folder Name Contents 
DL2 Crystallographic data files for DL2 
DL3 Crystallographic data files for DL3 
DL4ADI Crystallographic data files for DL4ADI 
DL4CIT Crystallographic data files for DL4CIT 




This section includes LC-MS, 1H NMR and 13C NMR data for DL1. It also includes a 
detailed account of experiments that were performed with DL1.  
 
Liquid chromatography-mass spectrometry (LC-MS)  
 
 












Figure 3: 1H NMR spectrum of DL1in DMSO-d6. 
 
13C NMR  
 
 




DL1 was recrystallized from eight solvents as summarized in Table 2. In general,              
10 mg of the compound was dissolved in a minimum of solvent while heating to           




and left on the bench to crystallize. In the case of recrystallization from isopropanol, 
the vial was maintained at a temperature of 40 °C to allow the solvent to evaporate 
slowly. For vapour diffusion, 10 mg of DL1 was dissolved in dichloromethane and the 
vial was placed inside a larger vial containing ethyl acetate. None of the 
crystallization attempts resulted in crystals that were suitable for SCXRD.  
 
Table 2: Recrystallization experiments with DL1. 
Solvent Crystallization method 
Methanol Slow evaporation at ambient temp. 
Ethanol Slow evaporation at ambient temp. 
Diethyl ether Slow evaporation at ambient temp. 
Ethyl acetate Slow evaporation at ambient temp. 
Acetonitrile Slow evaporation at ambient temp. 
Hexane  Slow evaporation at ambient temp. 
Isopropanol Slow evaporation at 40 °C 




10 mg of DL1 was co-ground with an equimolar amount of the co-former for 15 
minutes while small drops of ethanol were added. The products of the experiments 
were analysed by PXRD and the results show that all of the products were physical 
mixtures of DL1 and the co-former (Table 3). The products of the LAG experiments 
were recrystallized, but no single crystals were obtained using this method.  
 





Recrystallization of  LAG product 
Adipic acid 1:1 Physical mixture No single crystals 
Uracil 1:1 Physical mixture No single crystals 
Benzamide 1:1 Physical mixture No single crystals 
Isonicotinamide 1:1 Physical mixture No single crystals 
L-ascorbic acid 1:1 Physical mixture No single crystals 
L-tartaric acid 1:1 Physical mixture No single crystals 
Orotic acid 1:1 Physical mixture No single crystals 
Uric acid 1:1 Physical mixture No single crystals 
Citric acid 1:1 Physical mixture No single crystals 
Nicotinic acid 1:1 Physical mixture No single crystals 
L-malic acid 1:1 Physical mixture No single crystals 






Figure 5: PXRD traces of DL1, adipic acid and the product of LAG. 
 
Figure 6: PXRD traces of DL1, benzamide and the product of LAG. 
 





Figure 8: PXRD traces of DL1, isonicotinamide and the product of LAG. 
 
Figure 9: PXRD traces of DL1, L-ascorbic acid and the product of LAG. 
 





Figure 11: PXRD traces of DL1, L-malic acid and the product of LAG. 
 
Figure 12: PXRD traces of DL1, nicotinic acid and the product of LAG. 
 





Figure 14: PXRD traces of DL1, uracil and the product of LAG. 
 
Figure 15: PXRD traces of DL1, uric acid and the product of LAG. 
 






10 mg of DL1 was co-ground with an equimolar amount of α-CD, β-CD or γ-CD for 
15 minutes. Drops of water were added to maintain a paste-like texture during the 
kneading experiment. The products were analysed using PXRD and the results show 
that a complex formed between DL1 and γ-CD. Kneading α-CD and DL1 and γ-CD 
and DL1 resulted in physical mixtures of the components.  
 
 
Figure 17: PXRD traces of DL1, α-CD and the product of kneading α-CD and DL1. 
 









The LC-MS, 1H NMR and 13C NMR spectra for DL2 were provided by H3D and are 


















1H NMR  
 
 
Figure 22: 1H NMR spectrum of DL2 in CDCl3. 
 
PXRD traces for dry co-grinding experiments  
 
 





Figure 24: PXRD traces of benzamide, DL2 and the product of the dry co-grinding experiment. 
 
 
Figure 25: PXRD traces of DL2, citric acid and the product of the dry co-grinding experiment. 
 
 






Figure 27: PXRD traces of DL2, L-ascorbic acid and the product of the dry co-grinding. 
 
 
Figure 28: PXRD traces of DL2, L-malic acid and the product of the dry co-grinding experiment. 
 
 






Figure 30: PXRD traces of DL2, uracil and the product of the dry co-grinding experiment. 
 
PXRD traces from LAG experiments  
 
 
Figure 31: PXRD traces of adipic acid, DL2 and the product of LAG. 
 
 






Figure 33: PXRD traces of fumaric acid, DL2 and the product of LAG. 
 
 
Figure 34: PXRD traces of citric acid, DL2 and the product of LAG. 
 
 





Figure 36: PXRD traces of L-malic acid, DL2 and the product of LAG. 
 
 
Figure 37: PXRD traces of DL2, uracil and the product of LAG. 
 
 






Figure 39: PXRD traces of nicotinamide, DL2 and the product of LAG. 
 
PXRD traces for kneading experiments  
 
 
Figure 40: PXRD traces of β-CD, DL2 and the product of the kneading DL2 and β-CD. 
 
 







The LC-MS, 1H NMR and 13C NMR spectra for DL3 were provided by H3D and are 





Figure 42: LC chromatogram of DL3. 
 
 











1H NMR  
 
Figure 44: Partial 1H NMR spectrum of DL3 in DMSO-d6. 
 




13C NMR  
 
 

















PXRD traces for LAG experiments  
 
 
Figure 47: PXRD traces of DL4, L-ascorbic acid and the products of the LAG experiments. 
 
 








Figure 49: PXRD traces of DL4, isonicotinamide and the products of LAG experiments. 
 
 






Figure 51: PXRD traces of L-(-)-malic acid, DL4 and the product of LAG. 
 
 





Figure 53: PXRD traces of uracil, DL4 and the products of the LAG experiments. 
 
Figure 54: PXRD traces of uric acid, DL4 and the products of the LAG experiments. 
 




PXRD traces for kneading experiments  
 
 
Figure 56: PXRD traces of DL4, α-CD and the product of kneading DL4 and α-CD. 
 
 
Figure 57: PXRD traces of DL4, β-CD and the product of kneading DL4 and β-CD. 
 
 
 
 
 
 
